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To my family 
 
 
 
Redox regulation, though now becoming fashionable, remains confusing. 
Leopold Flohé, Redox Pioneer  
  
  
  
ABSTRACT 
Reversible reduction/oxidation (redox) reactions play key roles in cellular signaling pathways. 
Particularly cysteine residues in proteins can be modified by reactive oxygen-, nitrogen- or sulfur 
species (ROS, RNS, RSS), thereby altering the functions of the respective proteins. These 
modifications can be reversed by two major reductive systems in mammalian cells – the thioredoxin 
(Trx) and glutathione (GSH) systems. Both contain various representatives of the Trx fold family of 
proteins, among them the name-giving Trxs being the most prominent. In the cytosolic Trx system, 
electrons are transferred from NADPH to Trx reductase 1 (TrxR1) and subsequently to Trx1, which 
reduces a multitude of cellular substrates. Thioredoxin-related protein of 14 kDa (TRP14, TXNDC17) 
is a sparsely characterized, but evolutionarily well-conserved member of the Trx system. The studies 
comprising this thesis examined TRP14 in several aspects of redox signaling.  
In Paper I we investigated the inhibition of TrxR1 by noble metal compounds and their effect on 
cancer cell survival. Inhibition of the Trx system as anti-cancer strategy is thought to attenuate the 
antioxidant capacity of cancer cells, thereby leading to cell death. We found that gold (Au), platinum 
(Pt), and palladium (Pd) compounds all inhibited TrxR1 in vitro, but in a cellular context, the 
inhibition and cytotoxicity were mainly dependent on the ligand substituents and cellular uptake. 
Furthermore, we found a covalent crosslink between TrxR1 and TRP14 upon treatment of cells with 
the antitumor agent cisplatin. We concluded that noble metals are potent TrxR1 inhibitors but Pt 
compounds, especially cisplatin, trigger highly specific cellular effects, including the covalent 
complex formation. 
In Paper II we studied the role of the Trx system in reactivation of oxidized protein tyrosine 
phoshatases (PTPs) in platelet derived growth factor (PDGF) signaling. Using fibroblasts that lacked 
TrxR1 (Txnrd1-/-), we found both an increased oxidation of PTP1B and phosphorylation of the PDGFβ 
receptor (PDGFβR). Consequently, we showed that both Trx1 and TRP14, coupled to TrxR1, are able 
to reduce oxidized PTP1B in vitro. This study demonstrated that the Trx system, including both Trx1 
and TRP14, impacts the oxidation of specific PTPs and can thereby modulate PDGF signaling.  
In Paper III we established TRP14 as an efficient TrxR1-dependent reductase and denitrosylase. 
Using several low molecular weight disulfide compounds, we found that, dependent on the substrate, 
TRP14 can be at least as efficient as Trx1. We also suggested TRP14 instead of Trx1 to be a major 
intracellular cystine reductase, because Trx1 does not reduce cystine once a preferred substrate such as 
insulin is present. Acting in parallel with Trx1, we also provide evidence of TRP14 being an efficient 
cellular reductase for nitrosylated proteins and concluded that TRP14 should be considered as an 
integral part of the Trx system.  
In Paper IV we developed a novel method for the detection of protein persulfides named Protein 
Persulfide Detection Protocol, ProPerDP. The formation of persulfide (-SSH) moieties at regulatory 
cysteine residues is emerging as a major pathway of hydrogen sulfide (H2S) mediated redox signaling. 
Using ProPerDP we discovered that both the Trx and the GSH system are potent reduction pathways 
for poly- and persulfides in cells.  
These studies reinforce the notion that TrxR1-dependent pathways are not only mediated via its well-
known substrate Trx1. We show that TRP14 is yet another cytosolic oxidoreductase with various 
intracellular functions, including reduction of PTPs, disulfides, nitrosothiols and persulfides. TRP14 is 
thereby potentially involved in a variety of different redox signaling pathways.  
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1 INTRODUCTION 
1.1 INTRODUCTION TO THE FIELD AND THE PRESENT THESIS 
 “Life is nothing but electrons looking for a place to rest” 
Albert Szent-Györgyi (Nobel laureate, 1893-1986) 
 
This famous quote illustrates one of the most fundamental processes in life: the flow of 
electrons. It means that electrons in high-energy states, which sit on top of “energy hills”, roll 
down the hill towards a low-energy state and thereby dissipate energy 1. It is easily 
conceivable how this is part of our daily life, e.g. as electricity and the batteries in our 
smartphones. But it is far more than that: flowing electrons drive a myriad of cellular 
processes, including the synthesis of ATP, the cellular energy currency.  
Unfortunately, we know more about the electron flow in modern electronics than in 
biologic systems!   
Referring to the picture of the energy hill, we transfer electrons from fuel molecules (e.g. the 
glucose in our food, on top of the hill) to the terminal acceptor (molecular oxygen, the bottom 
of the hill), which results in water. Chemically speaking, the fuel molecule becomes 
oxidized, because it loses electrons, and the oxygen molecule becomes reduced, because it 
gains electrons. To make a long story short: this is the basis for redox reactions, which are at 
the center of the field of redox biology. The term redox signaling thereby refers to cellular 
signaling pathways that involve redox reactions.  
This thesis will cover several aspects of redox signaling: 
• Oxygen (O2) has to take up four electrons to be completely reduced. An incomplete 
reduction leads to reactive intermediates, reactive oxygen species (“ROS”), which play a 
central role in redox biology. In addition, reactive nitrogen and reactive sulfur species 
(“RNS” and “RSS”) also participate in cellular redox reactions. 
• ROS, RNS and RSS can act as signaling molecules by modifying redox-sensitive 
cysteine (Cys) residues in proteins, thereby altering the functions of the respective 
proteins. 
• In turn, these modifications can be reduced by the Glutathione (GSH) and Thioredoxin 
(Trx) systems. The major focus of this thesis is the Trx system, particularly the Trx 
related protein of 14 kDa (TRP14) and its role in redox signaling.  
• A prominent example of a cellular process that involves redox reactions is growth factor 
signaling. Notably, the oxidation of protein tyrosine phosphatases (PTPs) leads to their 
inhibition and thereby stimulation of receptor tyrosine kinase (RTK) mediated 
phosphorylation cascades.  
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1.2 CONCEPTS OF REDOX SIGNALING 
Generally speaking, signaling pathways have to fulfill minimal requirements. i) They need an 
unambiguous signal, which is ii) received by a cellular sensor and processed to evoke a 
specific cellular response and iii) the signaling process has to be terminated to restore basal 
conditions 2. In higher organisms, signaling networks are very complex due to simultaneous 
competitive reactions and crosstalk between different pathways – and still, the signal has to 
be fast and specifically transduced to the respective effector molecule 3,4. The best 
characterized way to transfer information in biological systems is via protein phosphorylation 
cascades. But how can signaling pathways be dependent on reduction-oxidation (redox) 
reactions? 
For a long time it was believed that ROS were randomly produced, detrimental metabolic 
byproducts. Nowadays it has been widely appreciated that reactive species like superoxide 
(O2-) or hydrogen peroxide (H2O2) regulate signaling pathways by reversibly modifying 
specific proteins 5-7. Redox signaling thereby involves both a specific response to certain 
receptor ligands (e.g. growth factors) that activate cells to produce oxidant species, and a 
stress response to excessive oxidant production (e.g. in pathological conditions) 8. This 
section aims at summarizing some of the key concepts of redox signaling (see Fig. 1 for a 
simplified scheme). 
 
 
Figure 1. Simplified overview of the general concepts of redox signaling. (1) Redox sensitive target proteins, also called 
“thiol switches” due to the presence of a reactive Cys thiol (or the deprotonated thiolate), can be reversibly modified by ROS, 
RNS and RSS. These different protein modifications (2) (oxidation to sulfenic- (-SOH), sulfinic- (-SO2H) and sulfonic- 
(-SO3H) acids, formation of disulfides (-S-S-), nitrosylation (-SNO), glutathionylation (-SSG) and formation of persulfides  
(-SSH) can affect a number of different processes such as protein function, protein-protein interaction, subcellular localization 
or transcriptional regulation. (3) Reductive enzyme systems like the Trx and the GSH systems can reverse most of the Cys 
modifications. The cooperative actions of oxidizing and reducing mechanisms can regulate cellular signaling pathways and 
are a general principle of redox signaling.  
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1.2.1 Oxidants: What is the ideal Signal? 
Out of all physiological reactive species (reviewed in depth in section 1.3), H2O2 is suggested 
to be one of the main oxidants in redox signaling 8,9. In contrast, free radicals (e.g. O2-) are 
less suitable signaling molecules due to their high reactivity and lack of specificity, and 
evidence for direct thiol oxidation is limited 8,10. The only radical that is currently accepted to 
be a genuine signaling molecule is nitric oxide (NO), but for reasons discussed later, it is 
typically not counted as a redox-signaling molecule 3. Instead, often the secondary products 
of free radicals are used for signaling purposes, e.g. the formation of H2O2 from O2-, or the 
formation of peroxynitrite (ONOO-) from NO and O2- 9. 
1.2.2 Sensing and Transmitting the Signal 
A central concept for redox signaling is that specific Cys residues in proteins act as so called 
“thiol switches” 11. Their reversible modification by oxidants transiently changes the 
functional properties of the respective protein, which works similarly to 
phosphorylation/dephosphorylation. Redox-dependent switches do not operate only via ROS 
induced oxidation of the thiol moiety; other modifications like nitrosylation, glutathionylation 
and persulfidation exist as well (section 1.4).  
Cys modifications have been often considered a result of global changes in the “redox 
balance” or the “redox homeostasis” – a perception that has recently been questioned 12-15. In 
general, redox reactions in a thermodynamic equilibrium can be described using the Nernst 
equation. The resulting redox potential provides useful information of the ratio of oxidized to 
reduced form of a certain redox-couple. However, a living organism is not in equilibrium and 
cellular redox reactions should therefore be regarded by their kinetic and enzymatic 
parameters, and not by their redox potential 16,17.  
The major question in the redox field that remains debated is how specificity can be achieved 
with “promiscuous” oxidant species. One essential property is a low acid dissociation 
constant (pKa) for key Cys residues. At physiological pH these residues can be deprotonated 
to the more nucleophilic thiolate (RS-), which is a prerequisite for the reaction with oxidants 
such as H2O2. However, a low pKa is unlikely to be the only determinant of thiol reactivity 
and selectivity in redox signaling. This is illustrated by the fact that Peroxiredoxins (Prxs) and 
PTPs such as PTP1B have a similar pKa value, but the rate constant of Prxs with H2O2 is 
million times higher than for PTP1B 4. On the other hand, several studies have demonstrated 
that stimulation with growth factors results in a burst of H2O2 production 18,19 and a 
concomitant oxidation of PTPs 20-24. How can PTPs be specifically oxidized when enzymes 
like Prxs and Glutathione Peroxidases (GPxs) are around, that both can react with H2O2 at 
almost diffusion-controlled rates? PTPs should be easily outcompeted by thiol peroxidases 14. 
Several hypotheses have been discussed and debated over the last years. 
One of the earliest theories is the “floodgate theory”. It suggests an over-oxidation and 
thereby inactivation of Prxs that in turn generates a localized zone in which H2O2 is available 
to react with less reactive cellular targets such as PTPs 25. Based on thermodynamic 
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considerations this seems to be unlikely in vivo, and specificity for redox signaling cascades 
has also been doubted 14,16,26. Additionally, in the context of signaling events, no 
hyperoxidized Prxs have been detected yet 27. However, following up on the inactivation of 
Prxs, another study suggests inhibition of PrxI by phosphorylation in confined membrane 
associated areas, which would also create a local “hotspot” of H2O2 28. 
In line with spatially confined H2O2 accumulation, several studies have proposed localized 
redox signaling. Subcellular localization of NOX complexes and PTPs in lipid raft regions 
and ER membranes, as well as compartmentalization of additional signaling proteins, could 
result in specific redox signaling platforms 29-32. Considering the limitations in diffusion 
distances of oxidant species, it seems feasible that they are predominantly generated in certain 
compartments 16. Locally confined redox signaling has also been reported in so-called 
“redoxosomes”, which are signaling endosomes that are triggered by growth factors and 
cytokines 33. 
The latest concept suggests that certain thiol peroxidases that have an exceptionally high 
affinity for peroxides act as sensors for oxidants and that they transfer this signal to a target 
protein – thus acting as “redox relays” or “redox mediators” 8,14. A recent study shows that 
PrxII acts as a direct peroxide sensor that oxidizes the transcription factor STAT3 34. Similar 
evidence is reported for PrxI and its action on ASK1 35.  
In summary, the current understanding of redox signaling mechanisms involves thiol 
oxidation either via direct reactions or facilitated via sensor proteins, thereby transmitting the 
signal. The floodgate theory seems to be rather outdated and latest research suggests that 
peroxidases are most likely involved in regulating H2O2 mediated signaling pathways, and 
also that the localization of the signaling partners plays an important role. Many questions 
still remain but future studies will certainly add more pieces to the puzzle. 
1.2.3 Switching off the Signaling Pathway: Reducing Systems 
Most oxidative modifications are reversible via the GSH and the Trx systems, whereof the 
latter is the main focus of this thesis. Both are essential regulators of multiple cellular 
processes and will be further discussed in section 1.5. In addition, cells utilize a variety of 
other enzymes and low molecular weight compounds as antioxidants. Important antioxidant 
enzymes are superoxide dismutases (SODs) that catalyze the dismutation of O2- to H2O2 and 
catalases (Cat) that can degrade millions of H2O2 molecules every second to O2 and water 
(section 1.3.2). Some well known non-enzymatic antioxidants include the vitamins A and E, 
as well as ascorbate (vitamin C) and lipoic acid 36.  
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1.3 REACTIVE SPECIES IN BIOLOGY 
1.3.1 Overview 
The perception of reactive oxygen/nitrogen/sulfur species (ROS, RNS, RSS) in biology has 
evolved a lot over the last years. The concept of “oxidative stress” has been described for the 
first time in 1985 as a disturbance in the cellular equilibrium between antioxidants and 
oxidants; often depicted as a scale, which is tipped in favor of the oxidants 5. As already 
addressed in section 1.2, physiological concentrations of reactive species can regulate 
signaling pathways by reversibly modifying protein targets 5,7,37. It should be emphasized that 
ROS, RNS and RSS are not single entities and should not be used without a proper definition, 
as they differ enormously in their reactivity and cellular functionality 38. This section 
therefore shall give an overview about the different biologically relevant reactive signaling 
species.  
Before addressing the different ROS, RNS and RSS in detail, it is helpful to start with some 
definitions (adapted from 8,39). 
A free radical is any species capable of independent existence with one or more unpaired 
electrons, e.g. nitric oxide (NO) 40. 
One electron (1e-) oxidants are either free radicals or transition metals that accept electrons. 
Physiologically relevant species are superoxide (O2-), the hydroxyl radical (OH), nitrogen 
dioxide (NO2) and the carbonate radical (CO3-).  
Two electron (2e-) oxidants are non-radicals that accept electrons to give non-radical 
products. Physiologically relevant species are hydrogen peroxide (H2O2), hypochlorous acid 
(HOCl), and peroxynitrite (ONOO-). 
Figure 2 shows an overview of the different reactive species, which throughout this section 
are classified into ROS, RNS and RSS and described in the main text according to their 
numbering in the Figure.  
In analogy to a quote from Christine Winterbourn, “Feasibility is a long way from reality” 41, 
this section emphasizes biological reactions of ROS, RNS and RSS.  
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Figure 2. Production and reaction of different reactive oxygen, nitrogen and sulfur species (ROS, RNS, RSS). The 
reactions are not balanced and the Figure intends to give an overview about the main physiologically relevant ROS, RNS and 
RSS. All reactions are explained in the main text of section 1.3 according to their numbering. 1) Production of superoxide 
(O2-) via one electron reduction of O2 in the electron transport chain in the mitochondria, specific NADPH oxidases (NOXs) 
or as byproduct of cyclooxygenases (COX), xanthine oxidase (XO) or cytochrome p450 enzymes (Cp450). 2) Dismutation of 
O2- to H2O2 and O2 either spontaneously or catalyzed by superoxide dismutases (SODs). 3) Spontaneous reaction of O2- with 
nitric oxide (NO) to peroxynitrite (ONOO-). 4) Reduction of H2O2 by peroxiredoxins (Prxs), catalase (Cat) and GSH 
peroxidases (GPxs). 5) H2O2 may react with chloride anions, yielding hypochlorous acid (HOCl). 6) The metal-catalyzed 
Fenton reaction yields hydroxyl anions and hydroxyl radicals. The latter is extremely reactive and can engage in further 
radical reactions. 7) Reaction of NO with metals, e.g. in ferrous heme proteins (Fe2+) like soluble guanylate cyclase to form 
ferrous nitrosyl-complexes. 8) Production of NO by nitric oxide synthases (NOSs). 9) Nitrate-nitrite-NO pathway to generate 
NO. 10) + 11) Oxidation of NO to nitrite (NO2-) and nitrate (NO3-). 12) Reduction of NO3-. 13 + 14) Auto-oxidation of NO 
to nitric dioxide (NO2) and dinitrogen trioxide (N2O3). 15) S-nitrosylation of thiols by N2O3. 16) ONOO-, the product of 
reaction 3), can be reversibly protonated to peroxynitrous acid (ONOOH). 17) Reaction of ONOO- with carbon dioxide (CO2) 
to carbonate radical (CO3-) and NO2. 18) Tyrosine (Tyr) nitration by NO2. 19) ONOOH can react with protein thiolates, 
yielding protein sulfenic acids. 20) Hydrogen sulfide (H2S) may be the product of cystathionine β-synthase (CBS), 
cystathionine γ-lyase (CSE), or the cooperative actions of aspartate/cysteine aminotransferase (AAT) and 3-mercaptopyruvate 
sulfurtransferase (MST). 21) Oxidation of H2S to polysulfides (HSx-). 22) Protein persulfide formation via the reaction of 
oxidized Cys derivates (e.g. sulfenic acid) with sulfide or 23) via the reaction of reduced Cys thiols with polysulfides. The 
Figure has been adapted in parts from 42.  
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1.3.2 Reactive Oxygen Species (ROS) 
“Oxygen has been a trouble-maker since the very beginning”  
(Doris Abele, Researcher in Stress Physiology and Ageing) 40 
We all require oxygen (O2) as the final electron acceptor for efficient energy production in 
our cells. The complete reduction to H2O requires four electrons (two per oxygen atom). 
According to the Pauli principle of electron spins, these electrons have to be transferred 
separately and not all at once 43. If O2 is only partial reduced during that process, reactive 
oxygen species (ROS) can be formed.  
Superoxide (O2-) 
The one-electron reduction of O2 yields superoxide (O2-, reaction 1). The largest 
intracellular contributors to O2- production are thought to be the mitochondria, mainly as a 
result of electron leakage in complexes I and III of the electron transport chain 6. Earlier 
reports estimated that 0.15-2% of consumed O2 results in the conversion to O2- 44-46. O2- is 
also the byproduct of several enzymes like cyclooxygenases (COX), xanthine oxidase (XO), 
cytochrome p450 enzymes and lipoxygenases 47-49. However, NADPH-dependent oxidases 
(NOXs) produce O2- as their main product 50 (see below). O2- can react with thiols, but the 
reaction is very slow as shown with GSH (k∼200 M-1s-2) 4,51. Even if O2- can be produced 
with a high rate, the steady state concentration is estimated to be in the low picomolar range 
due to a rapid rate constant for spontaneous (k∼105 M-1s-2) or superoxide dismutase (SOD) 
catalyzed (k∼109 M-1s-2) dismutation to H2O2 and O2 (reaction 2) 52. Recent reports suggest 
that SOD should not be purely considered as a scavenging enzyme, but that the produced 
H2O2 is important in metabolic regulation 53. O2- can also readily react with other radicals to 
form e.g. peroxynitrite (ONOO-) with the NO radical at almost diffusion-controlled rates 
(∼109-1010 M-1s-2) (reaction 3, see section 1.3.3) 39. Due to these fast secondary reactions, 
redox signaling is most likely indirectly mediated by O2-.  
Hydrogen peroxide (H2O2) 
Of all ROS, H2O2 is suggested to be the most relevant signal transmitter in redox 
signaling 9,41,54. It is the main product from O2-, and among all ROS, it has the longest 
cellular half-life (ca. 1 ms) 40. Direct reactions with most thiols are slow, but H2O2 shows 
exceptional reactivity with e.g. transition metals, selenothiols and selected thiol 
proteins 14,54,55. Its intracellular concentration ranges between nM and µM and is constantly 
regulated by GPxs, Prxs and catalase (reaction 4). Even if H2O2 is hardly reactive with most 
biological molecules due to a high activation energy barrier, it is especially associated with 
receptor-mediated redox signaling 55. H2O2 can also directly oxidize methionine (Met) to Met 
sulfoxide, but there is large body of evidence in the literature suggesting that Cys is the most 
sensitive amino acid residue to H2O2 mediated oxidation 52.   
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NADPH-dependent oxidases (NOXs) 
NOX enzymes are protein complexes that assemble in response to various stimuli to activate 
signaling pathways via e.g. transcription factor activation, inhibition of protein tyrosine 
phosphatases (PTPs), ion channel activation or regulation of enzyme activities 50,56. NOX 
complexes produce extracellular O2- by transporting electrons from cytoplasmic NADPH 
through their FAD and heme cofactors to O2. O2- in turn, dismutates to H2O2, which can 
enter the cytoplasm either by diffusion or by aquaporin channels 52,57.  
Neutrophils use O2- produced by NOX to generate highly reactive oxidants, including 
hypochlorous acid (HOCl) by myeloperoxidase (MPO) (reaction 5), which is used as part of 
the host defense to inactivate microorganisms in phagosomes 58. This classic phagocytic 
response to stimulation is known as the “respiratory burst”. An illustrative example is found 
in patients with a mutation in NOX2, which results in a condition called granulomatous 
disease. They suffer from recurring infections due to the inability to produce O2- as part of 
their immune system 6. It should be noted, however, that peroxidases like MPO are largely 
restricted to cells involved in the host defense and should not be considered as a universal 
role for H2O2 mediated cellular signaling 55.  
Transition metals and Fenton Chemistry 
Most of the damaging effects of ROS are due to the reaction of H2O2 with iron and the 
formation of hydroxyl radicals (OH) via Fenton Chemistry (reaction 6) 39,40. OH has a very 
short cellular half-life (10-9 s). It is a strong oxidant and reacts at diffusion-limited rates with 
proteins, DNA and lipids in the cell 54,59. There are no enzymes that neutralize OH, but in 
healthy cells the formation is considered very low due to a tightly regulated H2O2 and iron 
metabolism 52. 
1.3.3 Reactive Nitrogen Species (RNS) 
RNS are derivatives of nitric oxide (NO) with distinct properties in terms of reactivity and 
biological half-life. Analogous to ROS, RNS are suggested to play major roles in cellular 
signaling processes and pathological conditions. Some terms that are frequently confused in 
the NO-field are nitrosylation, nitrosation and nitration. The general consensus is that 
nitrosylation is a direct addition of NO to a macromolecule, while nitrosation is the 
attachment of a nitrosonium (NO+) ion (see section 1.4.3). Nitration, however, is the 
attachment of a NO2 (nitro) group 40.  
Nitric oxide (NO) 
NO is a colorless gas that, in general, has a modest reactivity with biological molecules 40. 
Due to its membrane solubility it can diffuse within a 100-200 µm radius of its production 
site 60. Concentrations vary between 100 pM to 5 nM and the half-life from 0.1-2 s 61. One of 
its main physiological roles and fastest reactions is the reversible binding to heme prosthetic 
groups, e.g. in guanylate cyclase (reaction 7) 62. The subsequent conformational change in 
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the enzyme results in the production of the second messenger cyclic guanosine 
monophosphate (cGMP), which in turn causes smooth muscle relaxation and 
vasodilation 40,63. NO is highly reactive with other radicals; it reacts at almost diffusion 
controlled rates with O2-, becoming ONOO- (reaction 3). The most damaging effect of NO 
is considered to be its reaction with the tyrosyl radical in ribonucleotide reductase (RNR) 40.  
NO is synthesized by a family of enzymes called nitric oxide synthases (NOSs) that use L-
arginine, O2, and NADPH to produce NO and L-citrulline (reaction 8). There are three types 
of NOS that differ in their rate of NO production and the mechanisms that regulate their 
activity. Inducible NOS (iNOS) exists in a variety of cells, including neuronal cells, 
hepatocytes and phagocytic cells. It can be expressed in response to bacterial products and 
certain cytokines to produce large amounts of NO as part of the host defense or 
inflammatory response 64. Endothelial NOS (eNOS) and neuronal NOS (nNOS) are both 
constitutively expressed, and in contrast to iNOS, furthermore regulated by Ca2+. Functions 
of nNOS include modulation of neurotransmission in the brain. As the name implies, eNOS 
is mostly expressed in endothelial cells where it regulates vasodilation and blood pressure. Its 
functions can be modulated by a variety of modifications including phosphorylation after 
growth factor stimulation and also nitrosylation 64,65. Interestingly, conditions of oxidative 
stress and inflammation have been shown to convert eNOS from an NO producing enzyme 
to a O2- producing enzyme; a process that has been referred to as eNOS uncoupling 66. 
Another recently emerging NO-generating mechanism is the “nitrate-nitrite-NO pathway” 67. 
Compared to the NOS mediated production of NO, the reduction of nitrate (NO3-) and nitrite 
(NO2-) provides an O2 independent pathway to generate NO and has been shown to be active 
during hypoxic conditions (reaction 9) 68. Nitrate and nitrite are either taken up via the diet or 
are endogenously produced via the oxidation of NO. The in vivo mechanisms of the 
oxidation remain elusive 69, but formation of NO2- by ceruloplasmin (reaction 10) 70 and 
formation of NO3- by oxyhemoglobin (reaction 11) 71 have been reported. In turn, NO can 
be regenerated from these oxidized derivatives by hemoglobin, myoglobin, xanthine oxidase, 
ascorbate and polyphenols (see 67 and references therein). It should be noted, however, that 
NO3- is considered an inert end product of NO oxidation that first needs to be reduced to 
NO2- – a process that requires bacteria in the oral cavity or gastrointestinal tract (reaction 
12) 67. 
NO does not react directly with thiol groups under biological conditions (S-nitrosylation, see 
section 1.4.3). Instead this type of redox modification is generally mediated by its oxidation 
products. However, the oxidation of NO is a very complex process. For example, the one-
electron oxidation of NO to give free NO+, which would be required for reaction with a thiol, 
is very unfavorable 72,73. The first auto-oxidation product of NO is nitric dioxide (NO2), a 
highly reactive free radical (reaction 13) 74,75. In aqueous solution it can react with another 
NO molecule (reaction 14) to give dinitrogen trioxide (N2O3), which can indeed react with 
thiolates to nitrosothiols (reaction 15) 72,75. Under normal physiological conditions this auto-
oxidation process is considered to be too slow to be significant, and controversy about the 
Irina Pader 
10 
biological mechanism of N2O3 generation (and thereby also S-nitrosylation) still exists 72. 
However, some studies suggest that this reaction is accelerated in hydrophobic 
compartments 52,74.  
Peroxynitrite (ONOO-) 
ONOO- is the product of the combination of NO and O2- (reaction 3). The reaction has a 
greater rate constant than the reaction of NO with heme or the reaction of O2- with SOD 40. 
ONOO- can be continuously formed under basal metabolic conditions, but it has a very short 
half-life and only nanomolar steady state levels 76. Its formation sites are highly dependent on 
the formation of its precursor radicals. In contrast to NO, O2- is unstable and does not 
diffuse as freely, thereby restricting the production of ONOO- to the production site of O2-. 
The chemistry of ONOO- is very intricate. Its reactivity is pH dependent (pKa∼6.8) and both 
the peroxynitrite anion (ONOO-) and peroxynitrous acid (ONOOH) are present under 
physiological conditions and can participate in 1e- and 2e- reactions (reaction 16) 76. The 
homolysis of ONOOH to OH and NO2 is slow and unlikely to be physiologically relevant 39.  
Physiologically relevant reactions of ONOO- are e.g. with carbon dioxide (CO2), thiol- and 
selenol-containing proteins, and transition metal centers in metalloproteins (e.g. Mn-SOD and 
heme proteins) 76,77. The biological concentration of CO2 is relatively high and the reaction 
yields the carbonate radical (CO3-) and NO2 (reaction 17), which both are potent 1e- 
oxidants that can have various effects. For example, NO2 can directly react with NO to form 
the potent nitrosating species N2O3 and CO3-, but can also participate in Tyr nitration 
reactions (reactions 14+18) 78. The 2e- oxidation of thiols by ONOOH yields sulfenic acids 
and nitrite (reaction 19) 39. Examples of proteins that have high rate constants with ONOO- 
are Prxs (k∼106-107 M-1s-1) 78 and GPxs (k∼108 M-1s-1) 79. The reaction of ONOO- with 
transition metal centers yields, via several steps, NO2- and a strongly oxidizing oxo-metal 
complex 78. All of the secondary radical species resulting from ONOO- mediated reactions 
(e.g. CO3-, oxo-metal complexes, NO2) are involved in promoting the nitration of Tyr 
residues in proteins, forming 3-nitrosotyrosine 80.  
1.3.4 Reactive Sulfur Species (RSS) 
The prototype of low molecular weight RSS is hydrogen sulfide (H2S). For a long time, it 
was only considered as a toxic gas and an environmental hazard, but recently it has gained 
more attention as potential signaling molecule 81,82. H2S is a colorless gas with an unpleasant 
smell of rotten eggs. It is both water and lipid soluble, and at physiological pH it occurs 
primarily in its thiolate form (HS-) (H2S ⇔ HS- + H+ ⇔ S2- + H+) 52,83. Important to note, 
the two dissociable protons can be substituted with other functional groups. This property 
allows H2S to form bridges, e.g. in per- and polysulfides (R-S-SH and R-S-Sn-S-R) 84. 
Another important aspect is that H2S is a fully reduced sulfur species with a formal oxidation 
state of -2 and can, as such, only be oxidized. The biological concentration of H2S has been 
controversial and it is believed that H2S is rapidly undergoing diverse reactions (Fig. 3), 
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which makes a reliable estimation of its physiological concentration difficult. Depending on 
the method, the concentration of free H2S was estimated to be in the submicromolar range in 
plasma and liver homogenates 85. However, recent reports suggest a labile pool of sulfur 
containing species in biological systems that can liberate H2S 86. 
H2S can be produced from Cys by at least three different enzymatic systems, Cystathionine-
β-synthase (CBS), Cystathionine-γ-lyase (CSE) and the cooperative actions of 
aspartate/cysteine aminotransferase (AAT), and 3-mercaptopyruvate sulfurtransferase (MST) 
(reaction 20) 87,88. Although they all use Cys as precursor, their kinetic and mechanistic 
properties are very different. In addition, the expression of these enzymes is tissue specific, 
e.g. CBS is predominantly expressed in the brain and CSE in peripheral tissues 88. Both CBS 
and CSE can catalyze many reactions with different substrates. CBS, for example, is the first 
enzyme in the transsulfuration pathway and converts homocysteine to cystathionine, but can 
also efficiently generate H2S from Cys and homocysteine 89. Which of these reactions is the 
predominant mechanism, and under which conditions, is currently unclear. 
The biological functions of H2S are very complex and many uncertainties still exist about the 
exact signaling mechanisms (Fig. 3). Predominantly, effects on the cardiovascular system and 
in inflammation have been described, with the major targets believed to be membrane ion 
channels, e.g. the ATP-sensitive potassium channel, which mediates vasorelaxation 90. The 
mechanisms how H2S activates ion channels are not fully elucidated yet, but evidence 
suggests that the respective channels are persulfidated 91,92. H2S can also react with 
hemoglobin to form sulfhemoglobin. This process is irreversible and thereby probably rather 
a metabolic sink for H2S and not relevant for signaling 85,93,94. H2S can theoretically react with 
other endogenous oxidant species, but due to its low concentrations, this has been suggested 
to be unlikely in vivo 95. In the mitochondria, H2S can be rapidly oxidized in several steps to 
sulfate (SO42-), which has both been considered as a pathway to eliminate H2S but also a site 
for generation of RSS such as GSH persulfide (GSSH) 93.  
 
 
Figure 3. Scheme of potential fates of H2S is the cell. H2S can readily react with hemeproteins, e.g. hemoglobin to form 
sulfhemoglobin or with other cellular oxidant species like for instance ONOO- or H2O2. Sulfide catabolism mainly occurs in 
the mitochondria, where it is rapidly oxidized to sulfate. The formation of persulfides on protein Cys residues (-SSH), called 
sulfhydration or persulfidation, is an emerging mechanism of persulfide mediated cellular signaling.85,96 
Persulfidation at reactive Cys residues is increasingly recognized as the likely signaling 
mechanism of H2S. However, H2S does not react with thiol groups directly, and parts of the 
physiological roles of H2S are potentially mediated via partially oxidized sulfane-sulfur 
containing species (reaction 21) 87,97-99.  
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Sulfane-sulfur is a form of sulfur with six valence electrons (represented by S0), which does 
not exist in free form, but is always attached to another sulfur atom (e.g. in elemental sulfur 
S8, persulfides R-S-SH and polysulfides R-S-Sn-S-R) 100. Polysulfides are unstable sulfide 
oxidation products, mainly generated with oxidants such as HOCl, H2O2 and other 
peroxides 87. The general formula of polysulfides can be depicted as H2Sx, but since they are 
expected to be in their anionic form at physiological pH, the formula HSx- is recommended. 
Polysulfides can vary in chain length, containing one sulfide and 1-8 sulfane-sulfurs. At the 
point the number reaches eight, the molecule cyclizes and separates from polysulfides as 
colloidal elemental sulfur 100.  
Protein persulfides can either be formed via the reaction of oxidized Cys derivatives with 
sulfide (reaction 22) or via the reaction of polysulfides with Cys thiols (reaction 23) 87. 
However, how this occurs in vivo is still not completely elucidated yet and despite the 
growing literature on protein persulfidation, the exact sources and identities of RSS are still 
controversial (see also section 1.4.4).  
 
1.4 MODIFICATION OF CYS RESIDUES 
1.4.1 Overview 
In proteins, Sec, Cys, Met, and aromatic amino acids can be reversibly oxidized and thus take 
part in redox signaling processes 101-103. The oxidation of Met to Met sulfoxide (MetO) and 
the reduction by MetO reductases (MSRs) is a sparsely characterized, but emerging signaling 
mechanism 104,105. Sec is only present in 25 mammalian proteins, mostly in the active site, 
e.g. in the major redox enzymes TrxR and GPx (section 1.5) 106,107. This section will focus on 
the modification of Cys residues because they are considered the major targets for redox 
signaling processes. 
The mammalian genome encodes 214 000 Cys residues of which 10-20% are redox active 
under physiological conditions 101. At least 18 biologically occurring non-radical 
modifications of Cys thiols have been described, with varying stability and biological 
impacts 108. The thiol (-SH) group is the sulfur analogue of the hydroxyl group (-OH), but 
compared to oxygen, sulfur is less electronegative and has a valence shell radius twice as 
large. Consequently, the SH bond is less polarized and becomes more easily deprotonated to 
the more nucleophilic thiolate form (-S-) at physiological pH 103. The acid dissociation 
constant (pKa) for free Cys is around 8.3 and for glutathione around 8.8 52,109. However, the 
local protein environment can dramatically influence the pKa value and thus the Cys 
reactivity.  
Cys is a non-essential amino acid, which is either synthesized from Met via the 
transsulfuration pathway or imported as Cys or cystine (Fig. 4) 110. The availability of Cys is 
the rate-limiting step for the synthesis of GSH 111. This makes the transsulfuration pathway an 
important metabolic pathway as it can maintain the pool of GSH in conditions of oxidative or 
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xenobiotic challenges 112,113. A recent study showed that mice genetically engineered to lack 
both TrxR1 and GSH reductase (GR) in mouse liver remained viable because they used the 
transsulfuration pathway to produce GSH for redox homeostasis 114. The enzymes of the 
transsulfuration pathway, CBS and CSE, are furthermore important in the generation of H2S 
(see section 1.3.4).  
Both Cys and its oxidized form cystine (the predominant form of the amino acid in 
circulation) are imported via several transport systems 115. Cys is imported via the alanine-
serine-cysteine (ASC) and XAG- systems (also called excitatory amino acid transporters 
(EAATs)) in a Na+-dependent manner 116-118. Cystine, on the other hand, is imported in a Na+ 
independent manner by system b0+, which seems to be involved in the renal absorption of 
cystine, and by the cystine/glutamate antiporter Xc- 119,120. Xc- is highly inducible by O2, 
electrophilic agents, TNFα, and the transcription factor Nrf2 120-123. Also, recent reports 
suggest that Xc- is induced by standard cell culture conditions and essential for the 
maintenance of intracellular GSH in cultured cells 120,124. After being imported, cystine is 
rapidly reduced to Cys. The exact mechanism is still not completely understood, but thought 
to involve the GSH and Trx systems 125. 
 
Figure 4. Overview of the transsulfuration pathway and the synthesis of GSH. Cys is the rate-limiting precursor for the 
synthesis of GSH, a two-step process catalyzed by glutamate-cysteine-ligase (GCL) and glutathione synthetase (GS). Cys, or 
its oxidized form cystine, can be imported via different transporters. Cystine is reduced intracellularly, but the mechanisms 
are not fully elucidated and suggested to be mediated via the GSH and Trx systems. Alternatively, Cys can be produced from 
the essential amino acid methionine (Met) and via transsulfuration, a pathway that is particularly active in the liver. In this 
pathway, Met is converted via the enzyme methionine-adenosyltransferase (MAT) to S-adenosylmethionine (SAM), the most 
important methyl donor in the body. In a transmethylation reaction catalyzed by methyltransferase (MT), S-adenoysl-
homocysteine (SAH) is generated. SAH can subsequently be hydrolyzed to homocysteine. Homoysteine in turn can either be 
remethylated via Met synthetase (MS) to form Met, or converted to Cys in the transsulfuration pathway via cystathionine-β-
synthase (CBS) and cystathionine-γ-lyase (CSE). For simplicity, the reactions are not balanced and only the main reaction 
products are shown. This Figure has been adapted from 110,113.   
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1.4.2 Thiol Oxidation  
Most oxidative thiol modifications are reversible and a central regulating mechanism in redox 
signaling 41. Oxidation can occur via the one-electron (radical) or the two-electron (non-
radical) pathway, whereof the latter is preferred in signaling pathways (Fig. 5). 
 
Figure 5. Non-radical (2e-) and radical (1e-) pathways of thiol oxidation. Non-radical oxidation of a thiolate gives sulfenic 
acid, which is a transient intermediate and in most cases undergoes further reactions. Its reversible condensation with an 
adjacent amide gives a sulfenylamide (e.g. in PTP1B). Further oxidation can result in sulfinic and sulfonic acids. Radical 
oxidation of a thiol results in the formation of a thiyl radical, which can have various fates. Asc-: ascorbate. The reactions are 
not balanced and just provide an overview of the main pathways. The Figure has been adapted from 41.  
The 2e- oxidation of thiolates with oxidants (H2O2, ROOH, HOCl, ONOOH) yields sulfenic 
acid (R-SOH), which is generally unstable and short-lived 39,41. It can subsequently react with 
protein thiols or GSH to form intra- or intermolecular disulfides. In absence of other thiols, 
the reaction with a backbone amide can result in a cyclic sulfenyl amide. All these forms can 
be reduced by the Trx and GSH systems. Sulfenic acids can be further oxidized to sulfinic  
(R-SO2H) and sulfonic (R-SO3H) acids, a process that is generally considered to be 
irreversible and slower than the initial oxidation 52. The only protein known to reduce sulfinic 
acids, e.g. in Prxs, are Sulfiredoxins 126. The reactivity of thiols with 2e- oxidants like H2O2 is 
determined by the pKa of the Cys residue. Thiol peroxidases like Prxs and GPxs show an 
exceptionally high reactivity with H2O2, which is a result of a highly conserved active site 
architecture and a specific transition-state activation of H2O2 in Prxs 41,127.  
The oxidation of Cys can also occur via 1e- oxidation of the thiol group to a thiyl radical. 
Under physiological conditions, the main reactions of a thiyl radical are with oxygen, thiol 
groups, and ascorbate, which are believed to be mainly protective mechanisms to prevent 
deleterious cellular reactions 39,128. The reaction with O2 results in thioperoxyl radicals 
(RSOO) that can undergo a variety of different reactions to e.g. sulfenic acids and disulfides. 
The reaction with ascorbic acid leads to the formation of O2-, which is removed in the radical 
sink pathway involving SODs and peroxidases 129. It is important to note that thiyl radicals 
can also react with NO and thereby provide a mechanism for protein S-nitrosylation 130. 
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1.4.3 S-Nitrosylation 
In order to discuss the formation of S-nitrosothiols, it is worthwhile to address some of its 
basic chemistry. The term “S-nitrosylation” generally describes the direct addition of NO to 
macromolecules, which is the underlying mechanism for the reaction of NO with metal 
centers, for example in guanylate cyclase. However, as described in section 1.3.3, NO does 
not react directly with thiol groups. Instead, the formation of a S-nitrosothiol involves the 
addition of a nitrosonium ion (NO+), which from a chemical perspective, is therefore a 
“nitrosation reaction”. The nitrosonium ion is the unstable 1e- oxidation product of NO. 
Accordingly, biological S-nitrosation reactions involve so-called NO+-donors 72. Since the 
literature to date has used the term “S-nitrosylation” also for reactions that are formally 
nitrosation reactions, this nomenclature will be used throughout this thesis.  
Even if the exact molecular and biological mechanisms are not fully elucidated yet, several 
mechanisms have been proposed for the formation of S-nitrosothiols 52,131: 
• Conversion of NO to the nitrosating compound N2O3  
• Radical reaction between NO and a thiyl radical 
• Metal-center catalyzed transfer of NO+ from a heme group to a Cys,  
demonstrated with e.g. hemoglobin 132 
• Transnitrosylation from one S-nitrosothiol to a thiolate 
Transnitrosylation is an emerging concept for the formation of S-nitrosothiols in vivo 133-135 
and was demonstrated for several proteins including GAPDH 136, Trx1 137, and caspase 3 138. 
In terms of redox signaling, this concept of forming S-nitrosothiols provides specificity, as it 
involves protein-protein interaction 139. Other mechanisms that have been suggested to 
determine the selectivity of Cys residues for S-nitrosylation are i) proximal localization of the 
target Cys to the source of NO production, ii) a so-called “signature motif” consisting of 
basic and acidic amino acids and iii) hydrophobic compartments close to the Cys 
residue 135,140.  
A recent literature review identified 233 endogenously S-nitrosylated proteins under 
physiological conditions as determined with the Biotin-Switch method 131,141, while another 
recent database identified >2000 mammalian proteins as targets for S-nitrosylation 142. A 
comprehensive analysis of all these proteins would be beyond the scope of this thesis, but 
examples include inhibitory effects of nitrosylation on caspases 143,144, the p65 unit of 
NFκB 145 and also PTPs 146,147. Aberrant S-nitrosylation has been correlated to 
neurodegenerative diseases such as Parkinsons and Alzheimers 140. Although significant 
efforts have been made in the field of S-nitrosylation, there is still debate about which 
proteins become S-nitrosylated, the context of the S-nitrosylation and the overall 
physiological significance.  
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Denitrosylation  
Compared to the formation of S-nitrosothiols, the mechanism of the abstraction of the 
nitroso-moiety (denitrosylation), is less characterized 148. Nevertheless, denitrosylation 
reactions seem to be tightly regulated, as some proteins including caspases, NOSs and IκB 
kinase β are S-nitrosylated and only become denitrosylated in response to a specific 
stimulus 65,143,149. Two enzyme systems have emerged as physiological relevant 
denitrosylating pathways: the GSNO reductase (GSNOR) and the Trx system. GSNOR is a 
major enzyme for the denitrosylation of GSNO. It uses NADH as an electron donor and is 
ubiquitously expressed in mammalian cells 150-152. It does not denitrosylate proteins directly, 
but a knockout of GSNOR has been correlated to increased levels of intracellular 
nitrosoproteins 150. The Trx system, coupled to NADPH, can denitrosylate a multitude of 
cellular proteins and low molecular weight nitrosothiols 153-155. Several other studies have 
demonstrated denitrosylating activity of enzymes including PDI 156, xanthine oxidase 157, 
SOD 158, GPx1 159 and carbonyl reductase 160.  
The Trx system and its regulation of NO-dependent processes is very complex and far from 
being fully understood. Compiled evidence suggests denitrosylation and transnitrosylation 
reactions mediated by Trx in cellular processes including apoptosis and inflammation 161. 
Caspase 3 is a prominent example of a protein that becomes denitrosylated by Trx1 153,162,163. 
However, at the same time, Cys46 in Trx1 has emerged as a target for nitrosylation that can 
perform transnitrosylation reactions to caspase 3 and Prx 137,164,165. These opposing reactions 
of Trx1 in either promoting or suppressing apoptosis via de- or transnitrosylation are still a 
conundrum in the field. Also the interplay with TXNIP, which seemingly inhibits the 
denitrosylating activity of Trx1 adds complexity to the picture 166.  
Trx1 mediated denitrosylation could follow two different mechanisms. After the attack of the 
nucleophilic Cys on the nitrosothiol, either an intramolecular disulfide between Trx1 and the 
protein could be formed 153 or this Cys could become nitrosylated and subsequently 
denitrosylated by the resolving Cys (Fig. 6) 167,168. A recent study applied the reaction 
mechanism via the intramolecular disulfide as “trapping” strategy with a mutant Trx1 lacking 
the resolving Cys to identify a large number S-nitrosylated protein targets, including the 
mitogen-activated protein kinase (MAPK) MEK1 and the transcription factor STAT3. 169.  
 
Figure 6. Potential mechanisms of denitrosylation by Trx1. Either, an intermolecular disulfide intermediate between Trx1 
and the substrate protein could be formed (upper part, mixed disulfide mechanism) or Trx1 becomes transiently nitrosylated 
(lower part, trans denitrosylation mechanism). 161 
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1.4.4 Persulfide Formation 
S-sulfhydration, e.g. the formation of persulfides (–SSH), is an emerging mechanism for H2S 
mediated signaling processes. From a chemical perspective, the term persulfide 
formation/persulfidation is preferred and will therefore be used throughout this thesis 87.  
As briefly discussed in section 1.3.4, H2S cannot directly interact with a thiol group. Thus, 
persulfide formation can only occur via i) reactions of oxidized Cys derivatives with sulfide 
or ii) reactions of Cys thiols with oxidized sulfide derivatives. The exact mechanisms are still 
under debate, but the major hypotheses can be summarized as follows: 
• Reaction of oxidized Cys derivatives (disulfides or sulfenic acids) with sulfide 86,170-172 
 (1) 
  (2) 
Both reactions have been intensively discussed, but currently the reaction of the sulfenic 
acid with sulfide (reaction 2) seems to be more feasible. Based on kinetic and 
thermodynamic considerations, reaction 1 has been suggested to be unlikely under 
physiological conditions 84. However, it should not be completely disregarded as it could 
be a possible pathway in more oxidizing environments including mitochondria and 
ER 173. Reaction 2 is influenced by the microenvironment of the sulfenic acid and local 
concentrations of sulfide vs. GSH, as protein S-glutathionylation is a competing reaction.  
• Reaction of thiols with polysulfides 86,99 
The formation of polysulfides has already been discussed in section 1.3.4 and efficient 
polysulfide mediated persulfidation of PTEN and GFP was recently reported 99. This 
mechanism is dependent on the initial oxidizing agent to generate polysulfides, the 
respective stability of the polysulfides, and the pKa of the thiol 87.  
Interestingly, a recent study suggested that enzymes of the transsulfuration pathway can 
generate persulfides, e.g. the formation of Cys persulfide (Cys-SSH) from cystine, which in a 
persulfide exchange reaction with GSH forms GSH persulfide (GSSH) 98. This has, however, 
been contradicted by another report which suggested that the reducing cellular environment 
favors the synthesis of H2S over persulfides 174. The question if low molecular weight 
persulfides act as sulfur donors in protein persulfidation reactions is still under active debate. 
In addition, the abundance of protein persulfides in vivo is also still a matter of controversy, 
mainly due to the methodological challenges in detection. Current methods like the Modified 
Biotin Switch Assay (based on the “traditional” Biotin Switch Assay to determine protein S-
nitrosylation) 91,141 or the recently developed Tag Switch Assay 175 give different results and 
illustrate that the very similar reactivity of Cys persulfides and thiols poses a major problem 
in studying persulfidation.  
It has been increasingly recognized that while the S-nitrosylation of a Cys residue typically 
results in inhibition of the respective protein, persulfide formation instead results in activation 
of enzyme activity 176. The most prominent example is GAPDH, where S-nitrosylation 
inhibits the glycolytic function and results in the translocation to the nucleus 177. The 
R− S − S − R ' + HS− → RSS− + R 'SH
R− SOH +HS− → RSS− +H2O
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persulfide formation on the same Cys residue instead enhances the glycolytic activity of 
GAPDH 91. Another example is NFκB, where S-nitrosylation of the p65 subunit inhibits 
NFκB signaling, while persulfidation promotes the transcription of antiapoptotic genes 178. In 
contrast, persulfidation of the active site Cys in PTP1B has been reported to inhibit its 
phosphatase activity similarly to oxidation or nitrosylation, and thereby to contribute to the 
ER stress response 179. 
The knowledge of the reduction of protein persulfides and polysulfides is also very limited. 
Recent studies have reported that Trx1 can reduce active site persulfides in MST and 
PTP1B 179,180. Both studies noted faster reactions with the Trx system compared to DTT and 
GSH, and also higher rates of Trx1 with the persulfidated PTP1B compared to the 
nitrosylated and oxidized versions.  
 
1.5 BIOLOGICAL SYSTEMS RELEVANT FOR REDOX SIGNALING 
1.5.1 Overview 
Most oxidative modifications of Cys residues can be reversed by the Trx and the GSH 
systems, which are the main topic of this section. Both systems mediate electron flux from 
NADPH through TrxR and GR to members of the Trx fold family of proteins and GSH 
respectively (Fig. 7) 42,108. First, the Trx family of proteins will be discussed and the 
regulation of redox signaling pathways by the Trx and GSH systems highlighted. TRP14, the 
major topic of this thesis, will be discussed separately in section 1.6. At the end of this 
section, protein tyrosine phosphatases (PTPs), which regulate receptor-tyrosine kinase 
signaling through oxidation/reduction of their Cys residue, will also be addressed 21. 
 
Figure 7. Schematic overview of the complementary Trx and GSH systems in mammals. The Trx system (left) depends 
on TrxRs that reduce isoforms of Trx. Trx1 and TRP14 can be reduced by cytosolic TrxR1. The GSH system (right) uses 
GSH to support the functions of GSTs, GPxs and Grxs. Oxidized GSH (GSSG) is reduced by GR. Both systems depend on 
NADPH (provided by the pentose phosphate pathway) and exhibit significant crosstalk and overlapping functions, such as 
protein disulfide reduction and sustaining DNA synthesis via ribonucleotide reductase.  
The Keap1/Nrf2 system 
The major regulator to coordinate cellular responses to oxidative and electrophilic stress is 
the transcription factor Nrf2 3,181. A full discussion of the Nrf2 signaling pathway would go 
beyond the scope of this thesis, but for the understanding of redox signaling the main concept 
is briefly summarized. Endogenous signaling molecules as presented in section 1.3 (e.g. 
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H2O2, ROOH, ONOO-), but also exogenous electrophilic compounds can activate Nrf2. 
Under basal conditions, Nrf2 is bound to its inhibitor Keap1 in the cytosol, which targets 
Nrf2 for proteasomal degradation. The oxidation and concomitant inhibition of Keap1 leads 
to a nuclear import of Nrf2, where it binds to the antioxidant response element (ARE) and 
induces the expression of a wide range of enzymes that promote cell survival and defense 
against oxidative and electrophilic stress. Examples of typical Nrf2 targets are members of 
the Trx and GSH systems, e.g. Trx1 and TrxR1, GR, GSTs, the cystine transporter Xc-, and 
enzymes for the synthesis of GSH 3,182-185.  
1.5.2 The Thioredoxin Family of Proteins 
Many key regulators of redox signaling belong to the Trx fold family of proteins. Its 
members are ubiquitously expressed in all organisms, tissues, cell types, and organelles 42. 
They typically share a common structural motif, which is called the “Trx fold”: a central core 
of a four-stranded beta sheet that is surrounded by three alpha helices 186,187. A recent study 
estimated that 723 proteins contain at least one Trx fold domain 188. In addition, Trx family 
proteins are characterized by having one or two Cys residues in their active site, which are 
essential for their catalytic activity 42. The reduction of protein disulfides is catalyzed by Trxs 
and Grxs via the so-called dithiol-mechanism and depends on a CXXC active site motif. This 
mechanism involves the nucleophilic attack of the N-terminal active site thiol which results in 
a transient mixed disulfide intermediate, followed by reduction through the C-terminal thiol. 
Deglutathionylation works via the monothiol mechanism and is only catalyzed by Grxs. After 
reduction of the target protein, the active site thiol forms a mixed disulfide intermediate with 
GSH, which is reduced by a second molecule of GSH. Some members of the Trx family, e.g. 
certain protein disulfide isomerases (PDIs), just have one Cys in the active site motif. Due to 
the absence of a second Cys longer stable disulfides can be formed which can be supportive 
in the oxidative protein folding in the endoplasmatic reticulum (ER). 
Many proteins of the Trx superfamily are not characterized yet, which results in a diffuse 
nomenclature and an incomplete understanding of their physiological functions. Besides the 
already mentioned, classical representatives of the family (Trxs, Grxs, Prxs), many so-called 
Trx-related proteins have recently emerged. Table 1 highlights members of the Trx family 
that are consecutively listed as thioredoxin-domain-containing-(TXNDC) proteins in NCBI 
and also includes the isoforms of the Trx and Grx proteins. Prxs and PDIs, as well as GPxs 
and GSTs are Trx fold proteins that are not included in this Table. Prxs are separately 
discussed, and for a thorough discussion of PDIs the interested reader is referred to an 
excellent review of the topic 189.  
As illustrated in Table 1, Trx-like proteins have diverse active sites with not only CXXC, but 
also C/S/A-XX-S/R variations. Also, the composition of the XX dipeptide in the active site 
can be very different. In terms of localization, these proteins seem to be distributed over 
almost all cellular compartments and in some cases they are even secreted. The proteins that 
are relevant for this thesis are mostly located in the cytosol, but a major part of the Trx-like 
proteins are also classified as PDIs and located in the ER. Some representatives are also 
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transmembrane proteins (TMX1-TMX4). They are all targeted to the ER membrane, but only 
TMX1 has oxidoreductase activity, while the others are thought to be more similar to 
PDIs 190-193. In addition, TMXs have recently been implicated in inflammatory liver injury 194. 
Humans also possess spermatozoa-specific Trx (TXNDC2 and TXNDC3 and TXNDC8) with 
various activities 195,196.  
Nucleus-located representatives of the Trx-like proteins are the Nucleoredoxins (Nxn 197, 
Nxnl1 198, Nxnl2 199). Nxn is a 55 kDa protein located both in the cytosol and nucleus 200,201 
that functions as a redox-sensitive regulator of the Wnt/b-catenin pathway and toll-like 
receptor signaling 202,203.  
Another emerging protein is Thioredoxin-like protein 1 (Txl), also known as Thioredoxin-
related protein of 32 kDa 204,205. It is a substrate for TrxR1 and due to its association with 
the proteasome, suggested to be the link between reduction and proteolysis 206,207. It can be 
induced by prostaglandins 208 and in contrast to Trx1 and TRP14, it reduces the phosphatase 
of regenerating liver (PRL) 209. A recent study also suggested a role in cisplatin resistance 210.   
Peroxiredoxins (Prxs) are substrates for Trxs and ubiquitous enzymes that scavenge H2O2, 
lipid peroxides and ONOO- 211. The view of Prxs has evolved significantly over the last years, 
from being “just” oxidative stress defenders to regulators of cell signaling processes. Several 
studies showed that overexpression of Prxs results in dampened growth factor signaling, 
while a deficiency causes elevated H2O2 levels and thereby oxidative inactivation of 
phosphatases and PDGF receptor activation 212,213. Also, regulatory functions in apoptosis and 
Wnt signaling have been documented 214,215. Six different Prxs exist in humans, PrxI-VI, 
which are categorized into three groups based on their structure and their catalytic 
mechanism: 2-Cys-Prxs (PrxI-PrxIV), atypical 2-Cys-Prx (PrxV) and 1-Cys-Prx (PrxVI). The 
first step in the catalytic mechanism is the oxidation of the N-terminal thiolate to a sulfenic 
acid intermediate. In a second step the resolving Cys residue, either within the same protein 
(PrxV) or from another subunit within the homodimeric complex (2-Cys-Prxs, PrxI-IV), 
forms a disulfide bridge, which is subsequently reduced by Trx1. 1-Cys Prxs do not have a 
resolving Cys residue and can be reduced by GSH catalyzed by GSTpi 14,42,211. Instead of 
being reduced, the sulfenic acid in Prxs can also be further oxidized to sulfinic acid (and even 
sulfonic acid), which blocks the enzyme for further catalysis 216. The finding that already very 
low concentrations of H2O2 can result in Prx hyperoxidation lead to the formulation of the 
floodgate hypothesis 25 (see section 1.2). The hyperoxidation of Prxs to sulfinic acid can be 
reversed by Sulfiredoxins 126.  
Prxs are very efficient catalysts with rate constants for some enzymes as high as  
107-108 M-1 s-1 14,39. These rates are comparable to selenocysteine (Sec) containing GPxs and 
Prxs are therefore considered to be prime H2O2 sensors in the cell 8. The activity of Prxs is 
most likely only limited by the reducing capacity of the Trx system 14. Prxs can also be 
regulated by posttranslational modifications such as phosphorylation 28, glutathionylation 217, 
nitrosylation 218, and nitration 219.
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Table 1. Members of the Trx fold family of proteins in the human genome. The genes are listed according to their official 
designation (in bold) by the Human Gene Nomenclature Committee (HGNC) in NCBI. Trx domain containing (TXNDC) 
proteins, Trxs, Nrxs and Grxs are shown. Prxs, PDIs, GPxs and GSTs have been omitted. a.a.: amino acids. Adapted from 42.  
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1.5.3 The Thioredoxin System 
The Trx system, consisting of NADPH and isoforms of TrxR and Trx, is a major disulfide 
reductase system that transfers electrons to a multitude of enzymes 220. As such, it is critical 
for DNA synthesis and cell proliferation as well as redox signaling and defense against 
oxidative stress 221,222. A knockout of Trx or the TrxR genes in mice is embryonically lethal, 
showing the importance of the system for normal cell function and development 223-227.  
Trx (discovered by Peter Reichard in 1964) is an electron donor for ribonucleotide reductase 
(RNR) and thereby essential for the de novo synthesis of 2’-deoxyribonucleotides from 
ribonucleotides in DNA replication 228,229. Trx is ubiquitously expressed and conserved 
through all species 230. The main mammalian isoforms are cytosolic Trx1 and mitochondrial 
Trx2 and both contain the highly conserved CGPC active site motif. Oxidized Trx is reduced 
by electrons from NADPH via TrxR 231. Despite the lack of a nuclear localization signal, 
Trx1 is additionally found in the nucleus where it interacts with several transcription factors, 
e.g. Ref-1, AP-1, NFκB and p53 232-236. A truncated form of Trx1, Trx-80, can be found 
extracellularly and is involved in T-cell activation and possibly in Alzheimers disease 222,237.  
Beside the active site, Trx1 contains three additional Cys residues: C62, C69 and C73. C73 
protrudes from the surface and can thereby form disulfide-linked homodimers that cannot be 
reduced by TrxR1 238,239. The formation of an intramolecular disulfide bond between C62 and 
C69 is believed to have a regulatory function, as this modification also cannot be reduced by 
TrxR1, but instead requires the GSH system 240,241. The additional Cys are furthermore 
subject to post-translational modifications, e.g. nitrosylation and glutathionylation 242. 
Cytosolic Trx1 acts as electron donor for Prxs 243, MSR 244 and also binds PTEN 245, thereby 
inhibiting PTEN and thus promoting tumorigenesis. Trx1 is furthermore involved in 
apoptosis signaling via apoptosis signal regulating kinase 1 (ASK1). ASK1 is an upstream 
MAPKKK that regulates c-Jun-N-terminal kinases (JNK) and p38 MAPK leading to stress-
induced apoptosis and inflammation. Reduced Trx1 binds ASK1 thereby inhibiting the kinase 
activity 246. Oxidation or nitrosylation of Trx1 releases ASK1, thereby initiating apoptosis 
signaling 247,248.  
The function of Trx1 can be regulated by Trx-interacting protein (TXNIP, also known as 
thioredoxin binding protein 2/vitamin D3 upregulated protein). TXNIP does not belong to the 
Trx fold family of proteins and forms a disulfide bond with C32 in the active site of Trx1, 
thereby inactivating the enzyme 249,250. TXNIP has both redox dependent and independent 
functions, its expression is for example widely regulated by nutrition status 251. The release of 
ASK1 and subsequent apoptosis induction is likely also promoted by TXNIP 252.  
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Trx reductase (TrxR) 
TrxRs are dimeric flavoenzymes of the pyridine nucleotide disulfide oxidoreductase 
family 253. Three different isoforms of TrxR1 are expressed in mammalian cells, of which the 
cytosolic TrxR1 will be the focus of this thesis. Further isoforms are localized in the 
mitochondria (TrxR2) and one isoform named Trx GSH reductase (TGR) is predominantly 
expressed in testis. TrxR1 is a homodimeric enzyme. Each subunit contains one FAD and 
two redox-active sites: one N-terminal, close to the FAD; the other at the C-terminus. The C-
terminal active site contains a highly reactive and accessible selenocysteine (Sec) residue, 
which is cotranslationally incorporated and essential for the catalytic function 254,255. Sec, 
often referred to as the 21st amino acid, is the selenium-containing analogue of Cys. 
Compared to Cys, Sec has a lower pKa and is therefore more reactive 256.  
TrxR1 has a multitude of cellular functions, mainly via its substrate Trx1, which thereby 
makes the whole Trx system dependent on the trace element selenium 253. Other protein 
substrates of TrxR1 include TRP14 163,257, TRP32 206, PDIs 258 and mitochondrial Grx2 259. 
TrxR1 is also known to reduce various small molecules, including quinones like 5,5-
dithiobis-(2-nitrobenzoic acid) (DTNB, Ellmans reagent) 260, selenite 261, 
selenoglutathione 262, ebselen 263, H2O2 255, lipid peroxides 264, lipoic acid and lipoamide 265, 
dehydroascorbate 266 and menadione 260. The principal catalytic mechanism in the head-to-tail 
arrangement of two TrxR1 subunits involves the transfer of electrons from NADPH to the N-
terminal active site motif (-CVNVGC-) via the enzyme bound FAD. The resulting dithiol 
exchanges its electrons with the selenyldisulfide motif in the other subunit, which in turn 
facilitates reduction of the different TrxR1 substrates (Fig. 8) 253. Some substrates, like 5-
hydroxy-1,4-naphtalenedione (juglone), do not require an intact Sec residue and may be 
directly reduced via the N-terminal motif 267.  
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Figure 8. Catalytic mechanism of TrxR1. The enzyme is depicted as “Yin-Yang”, illustrating the homodimer in head-to-tail 
configuration. For convenience, two possible catalytic mechanisms are depicted on the same enzyme. Sec-dependent redox 
cycling (upper part): The electrons flow from NADPH via the FAD moiety to the N-terminal disulfide motif of one subunit 
and subsequently to the C-terminal selenylsulfide motif of the other subunit. The thereby reduced selenothiol motif allows 
reduction of substrates such as Trx and TRP14. Sec-independent redox cycling (lower part): The selenolate of the C-terminus 
can be derivatized with electrophilic agents (indicated with X), which results in an enzyme species that is irreversibly 
inhibited for the normal substrate reduction via the C-terminal active site. However, NADPH can still donate electrons to 
FAD and the functional -CVNVGC- motif, which promotes Sec-independent reduction of certain substrates such as juglone 
and other quinones. For further details, see text. This Figure was adapted from 253.  
TrxR1 inhibition and the SecTRAP concept 
The accessible and highly nucleophilic Sec residue is essential for the catalytic activity of 
TrxR1, but makes the enzyme at the same time susceptible to inhibition by electrophilic 
compounds. A complete list of inhibitors of TrxR1 would be beyond the scope of this thesis 
and the interested reader is referred to a recent compilation of TrxR1 inhibitors in relation to 
the Nrf2 system 184. However, prominent examples of TrxR1 inhibitors include naturally 
occurring compounds such as flavonoids 268, curcumin 269, sulforaphane 270 and interestingly, 
also various components in red wine 271. Also 4-hydroxynonenal, the end product of lipid 
peroxidation, is a potent, irreversible inhibitor of TrxR1 272.  
Some of the most potent inhibitors of TrxR1 are transition-metal containing compounds 
(Fig. 9). Gold (Au) compounds, like the FDA approved drug auranofin, are well known 
inhibitors and have long been used in the treatment of rheumatoid arthritis, a condition that is 
associated with elevated levels of TrxR1 273-275. Auranofin also seems to be effective as 
chemotherapeutic agent and is currently in clinical trials for the treatment of cancer 276. 
Platinum (Pt) compounds, like the prototype cis-diamminedichloroplatinum(II) (cDDP, 
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cisplatin), are also effective inhibitors of TrxR1 277,278. Cisplatin was “accidentally” 
discovered in the 1960s, when Barnett Rosenberg found that electrolysis products of platinum 
electrodes inhibited cell division in E. coli 279. Today, Pt containing drugs are used to treat a 
variety of cancers. Cisplatin was one of the first anticancer compounds found to interact with 
the Trx system. Additionally, the therapeutic effect may involve other mechanisms including 
DNA adducts 278,280, induction of ROS 281 and ER stress 282. Severe side-effects of cisplatin 
and acquired drug-resistance have limited its application and promoted the development of 
next-generation Pt-based agents 283. Besides Pt compounds, also silver, ruthenium and 
gadolinium-based compounds have been shown to inhibit TrxR1 284.  
 
 
Figure 9. Structures of auranofin (Ridaura®) and cisplatin. 
 
A proposed effect of certain TrxR1 inhibitors that target the Sec residue of the protein is the 
ability to convert TrxR1 into a selenium compromised thioredoxin reductase-derived 
apoptotic protein (SecTRAP). These SecTRAPs have lost their ability to catalyze Sec 
dependent reactions, but are still capable of redox cycling via the intact FAD and N-terminal 
active site 285,286. One explanation is that compromising the Sec residue causes a 
conformational change, so that the N-terminus is more accessible, because otherwise the 
electron transfer within the homodimer is very efficient and should not result in electron 
leakage 287,288. Several studies have shown that SecTRAPs can induce cell death and that the 
formation of reactive oxygen species is part of their cytotoxic mechanism 286,289,290. Recent 
reports correlate the inhibition of TrxR1 by the compounds N-acetyl-p-benzoquinone imine 
(NAPQI), the active metabolite of acetaminophen 291, Shikonin 292 and MJ25 293 to the 
formation of SecTRAPs. Interestingly, the overexpression of TrxR1 in cells involves 
expression of a truncated version of the enzyme, which also has SecTRAP-like effects and 
causes rapid cell death. Supportive of the SecTRAP concept is also the finding that targeting 
the Sec residue in TrxR1 results in more severe effects than caused by TrxR1 knockdown 
(see 253 and references therein).  
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1.5.4 The Glutathione System 
The GSH system is another NADPH-dependent redox-regulatory system. One of its major 
functions is the detoxification of xenobiotics and their metabolites; either directly by GSH or 
catalyzed by Glutathione-S-transferases (GSTs) 111. In addition, GSH is used as a cofactor for 
GPxs and glutaredoxins (Grxs). The oxidized form of GSH, glutathione disulfide (GSSG), is 
reduced by the flavoprotein Glutathione reductase (GR). 
GSH 
Reduced GSH is a 307 Da tripeptide (γ-glutamyl-cysteine-glycine) present in millimolar 
concentrations in most cells 111. 90% of the cellular GSH is in the cytosol, 10% in the 
mitochondria and a small percentage in the ER 294,295. The turnover in rat liver is estimated to 
be about 2-3 h, and it is important to note that due to the γ-carboxylgroup, GSH cannot be 
degraded intracellularly. The only enzyme capable of that reaction is gamma-
glutamyltranspeptidase (GGT), which is present on external surfaces of certain cell types 111. 
GSH is synthesized from Cys, which is either imported into the cell or provided by the 
transsulfuration pathway (see section 1.4.1). Under conditions involving severe oxidative 
stress, GSSG will accumulate and subsequently be exported. Since cells cannot take up 
GSSG, they require de novo synthesis of GSH 296. 
Protein glutathionylation can be a regulatory function or a protective mechanism against 
irreversible overoxidation 297. Possible mechanisms include thiol-disulfide exchange reactions 
with GSH or the condensation of GSH with Cys sulfenic acids or nitrosothiols 52. More than 
200 mammalian proteins are reported to be glutathionylated, e.g. PrxII as a mechanism to 
protect against overoxidation 217,298,299.  
GSTs 
GSTs are important detoxifying enzymes that catalyze the conjugation of GSH to various 
endogenous and exogenous electrophilic compounds 300,301. A key feature of GSTs is to aid in 
the deprotonation of GSH. The resulting thiolate anion (GS-) is a strong nucleophile and 
required for the conjugation to the electrophilic substrates 302. Many GSTs are expressed in 
response to Nrf2 activation as part of the cellular defense against electrophiles and oxidative 
stress. In most cases, the GSH-conjugated compound is less reactive, more water soluble and 
subsequently excreted from cells via cellular efflux systems 303. Sometimes the conjugation of 
GSH can also result in metabolites that are more reactive than the parental compound, a 
feature that could be used in cancer therapy to produce reactive metabolites that selectively 
target tumor cells with upregulated expression of GSTs 304,305. In addition to their detoxifying 
activities, GSTs have metabolic functions and catalyze the synthesis of e.g. steroids, 
leukotriens, prostaglandins, testosterone, and progesterone 300,302. GSTs also exhibit 
peroxidases activities in reducing lipid hydroperoxides and are furthermore suggested to 
perform the glutathionylation of proteins 185,306.  
 
Characterization of Thioredoxin Related Protein of 14 kDa and its Role in Redox Signaling 
 27 
GPxs 
GPxs catalyze the GSH-dependent reaction with various types of hydroperoxides 307. Eight 
GPxs are expressed in humans; most of them are selenoproteins (GPx1, GPx2, GPx3, GPx4, 
GPx6) while the remaining enzymes have a Cys instead of a Sec in their active site (GPx5, 
GPx7, GPx8) 308. The Sec containing GPxs reduce H2O2 with rate constants higher than 
107 M-1s-1 while the regeneration of the enzyme by GSH is estimated to be near 105 M-1s-1, 
which seems reasonable to keep the enzyme reduced under most physiological conditions. 
This makes them, together with the Prxs, prime targets for the reaction with H2O2 in redox 
signaling pathways 14. The most studied GPx is GPx1. It is ubiquitously expressed in the 
cytosol and the mitochondria and was the first selenoprotein ever described 309. A knockout 
of GPx1 in mice has only mild effects, but the overexpression of GPx1 (the so-called 
“supermouse”) resulted in a phenotype resembling type II diabetes and showed that GPx1 is 
involved in regulating insulin signaling 310. According to the current hypothesis, GPx1 
“steals” the H2O2 that is required for efficient inactivation of PTP1B, which is a prerequisite 
for efficient insulin signaling 14. Interestingly, the only knockout of a GPx that is 
embryonically lethal is Gpx4. It seems to be unique in reducing specific lipid peroxides 
generated by 12,15-lipoxygenase and has thereby additional regulatory functions in the 
cell 307,311. 
Grxs 
Grxs were first identified as electron donor for RNR and as GSH-dependent reductases 312-314. 
Grxs catalyze both the formation and reduction of mixed disulfides between protein thiols 
and GSH and can be divided into dithiol and monothiol Grxs. Dithiol Grxs have a 
characteristic CXXC active site motif, whereas monothiol Grxs lack the C-terminal Cys and 
instead possess a CXXS active site. Oxidized Grxs are reduced by GSH 315. Human Grx1 
exists in the cytosol, nucleus, mitochondria, as well as in the plasma and therefore has a 
variety of functions. Examples include the regulation of transcription factors like NF-1 316, 
NFκB and AP-1 201 as well as the reactivation of PTP1B after glutathionylation 317. 
Furthermore it is involved in apoptosis signaling by binding ASK1 318 and regulating caspase 
3 cleavage 319. The activity of Grx1 is possibly also regulated via S-nitrosylation 320.  
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1.5.5 Targeting Redox Signaling Pathways as Anti-Cancer Strategy 
Cancer is still a leading cause of death worldwide, with a tendency to double until 2030 
(source: who.org). Cancer is, however, a collective name for multiple genetic disorders that 
result in individual tumors, consisting of heterogenic populations of aberrant proliferating 
cells. Douglas Hanahan and Robert Weinberg originally described common hallmarks of 
cancer 321, which now have been expanded with additional stress phenotypes, called non-
oncogenic addictions 322. One of these additional cancer-supporting characteristics is an 
excessive ROS production in cancer cells, accompanied by elevated antioxidant 
mechanisms 323,324. What first sounds like a paradox, is the result of a redox adaptation. The 
activation of oncogenic pathways leads to increased production of ROS via multiple 
mechanisms, which in turn promotes diverse signaling events and contributes to 
tumorigenesis 325. At the same time, oncogenesis is further promoted by antioxidant 
mechanisms that are induced to counteract the ROS overproduction and its effects 326,327. As a 
result, both ROS and enzymatic systems such as the Trx and GSH systems are elevated at the 
same time. A promising, recently emerging anti-cancer strategy exploits this feature by either 
increasing the generation of ROS or decreasing the capacity of the antioxidant systems to 
specifically eliminate cancer cells, leading to an “overload” of ROS (Fig. 10) 323,328. 
According to this concept, cancer cells would be more sensitive to further ROS accumulation 
than normal cells, as they are already at the limit of their antioxidant capacity. Several drugs 
that are in clinical use, including anthracyclines such as doxorubicin, but also Pt complexes 
like cisplatin, are known to increase ROS, which might exceed the tolerated threshold and 
thus be part of their therapeutic efficacy 278,281,329,330. 
 
Figure 10. Simplified scheme of the redox homeostasis in normal and cancer cells. Normal cells have basal levels of 
ROS and antioxidant systems. In contrast, cancer cells have elevated basal ROS levels that are balanced by an increased 
antioxidant capacity. This redox adaptation helps cancer cells to survive, but makes them at the same time more vulnerable 
for further oxidative stress modulation. A further increase of ROS (either by using ROS generating agents or suppression of 
the increased antioxidant activities of cancer cells) may be sufficient to cause cell death in cancer cells but not in normal cells. 
Normal cells can tolerate a certain level of oxidative stress by upregulating their antioxidant capacity and restoring their basal 
“redox balance”. Cancer cells already exhibit elevated ROS levels and antioxidant systems, so that the already fragile “redox 
balance” cannot tolerate any further oxidative stress, thereby leading to cancer cell death.  
The Trx system, in particular TrxR1, has been extensively discussed as an anti-cancer 
target 222,331-333. TrxR1 is often overexpressed in tumors and the therapeutic effect of several 
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anti-cancer drugs has been connected to the inhibition of TrxR1 and oxidative stress 278,334-338. 
These observations therefore support the notion of TrxR1 being an attractive anti-cancer drug 
target. Whether the inhibition of TrxR1 alone would be sufficient for anti-cancer efficacy or 
if the inhibition of the enzyme is just part of the cytotoxic effect is still a complex and active 
research field. 
Recent studies have also suggested a simultaneous targeting of the Trx and GSH systems as 
an effective anti-cancer strategy 339-341. As either one of the two systems is required for cell 
survival 342, this approach still poses many unanswered questions and requires further insights 
into the regulation of the Trx and GSH systems both in normal and malignant cells. 
1.5.6 Redox Signaling and Protein Tyrosine Phosphatases (PTPs) 
A number of critical cellular processes like proliferation and differentiation are regulated by 
receptor tyrosine kinases (RTKs) 343. All RTKs have a similar architecture consisting of an 
extracellular ligand binding domain, a single transmembrane helix, a cytoplasmic region that 
contains the protein tyrosine kinase domain and additional c-terminal regulatory regions. The 
binding of a growth factor induces receptor dimerization and auto-phosphorylation of Tyr 
residues, which then mediate the cellular response through circuits of protein interactions and 
signaling cascades (Fig. 11) 344.  
 
Figure 11. Simplified overview of the regulation of receptor tyrosine kinase (RTK) signaling by reversible oxidation of 
protein tyrosine phosphatases (PTPs). RTK activation through growth factor (GF) binding can cause the production of 
ROS by mitochondria, NOX and lipoxygenase (LOX) enzymes, thereby inactivating PTPs and allowing for RTK mediated 
signaling processes. Note: NOX enzymes produce ROS extracellularly (see more detailed discussion in section 3.2).  
Growth factors like insulin-like growth factor 1 (IGF1), epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), and also insulin act through RTKs 345. They can 
activate key signal transduction pathways, including the phosphatidylinositol 3-kinase 
(PI3K)-AKT signaling pathway and mitogen-activated protein kinase (MAPK) cascades, 
thereby promoting cell proliferation, nutrient uptake and cell survival 346. RTK signaling is 
negatively regulated by protein tyrosine phosphatases (PTPs), which will be the focus of this 
section. Since RTK signaling is important for critical cellular processes, a dysregulation of 
both RTKs and PTPs is associated with a variety of diseases 347.  
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PTPs are not just simple “housekeeping” proteins that oppose RTK signaling; their activity is 
tightly regulated and involves the reversible, inhibitory oxidation of their active site Cys 
residue upon receptor stimulation 348. The specificity towards phosphotyrosine is determined 
by a deep active site pocket, for which phosphoserine and phosphothreonine are too 
small 32,349. The structural environment of the active site is organized in a way, that it lowers 
the pKa of the catalytic Cys, making it more nucleophilic, but at the same time also 
susceptible to oxidation 348. It has been well established that the stimulation of growth factor 
receptors results in a production of ROS and a concomitant oxidation of PTPs 21,350. Possible 
sources of ROS include i) NOX enzymes 351, ii) mitochondria 352-354 and iii) lipid 
peroxides 355,356. Collectively, these events cause an increase in receptor phosphorylation and 
activation of downstream signaling pathways (more detailed discussion in context of paper II, 
section 3.2). The PTP family consists of 107 members 357, of which three that are important 
for this thesis will be briefly introduced: 
PTP1B was the first PTP that was purified and characterized 358,359. It is encoded by the 
PTPN1 gene and has a hydrophobic C-terminal sequence that targets PTP1B to the 
membranes of the ER 360. Despite this anchoring, PTP1B is able to access its substrates by 
different mechanisms, e.g. by endocytosis, the movement of the ER network or by generation 
of a truncated, soluble form 360,361. PTP1B dephosphorylates and thus inactivates the EGF 
receptor (EGFR), PDGF receptor (PDGFR) and the insulin receptor (IR) 362. PTP1B 
knockout mice (Ptpn1-/-) are healthy, but remain insulin-sensitive when put on a high-fat 
diet 363. Overexpression of PTP1B abrogates insulin receptor signaling 364. In 1998, the first 
study reported that the EGF mediated H2O2 production resulted in oxidation and thereby 
inactivation of PTP1B 24. The same study provided the first evidence that the Trx system 
could reactive PTP1B, which has been further confirmed by other laboratories 179,365,366.  
SHP2 belongs to non-transmembrane, Src homology 2 (SH2) domain-containing PTPs 367,368. 
The SH2 domains regulate the intracellular location and catalytic activity. They are 
specifically targeted to Tyr phosphorylation sites in receptors and scaffolding adaptor 
proteins 369. SHP2 is required for the full activation of the RTK induced MAPK-ERK 
signaling pathway. It dephosphorylates PDGFR, but also binds scaffolding molecules like 
members of the Gab/Dos and insulin receptor substrate (IRS) families 369. In the basal state, 
SHP2 exhibits low activity because the active site is occluded by intramolecular interaction 
with the N-terminal SH2 domain opposite of the pTyr binding site. Upon stimulus with 
appropriate pTyr ligands, a conformational change results in release of the autoinhibitory 
loop and activation of the enzyme. Thus, SHP2 only becomes activated when it is recruited to 
the correct signaling complex 32.  
The phosphatase and tensin homologue (PTEN) is another PTP that becomes reversibly 
oxidized in response to EGFR activation 23. PTEN is a dual protein and lipid phosphatase as 
well as a negative regulator of the PI3K/AKT signaling pathway 370. It is worthwhile to note, 
that PTEN is one of the most frequently lost or mutated tumor suppressors in human cancer, 
which further emphasizes the importance of tight regulation in RTK/PTP signaling 371.  
Characterization of Thioredoxin Related Protein of 14 kDa and its Role in Redox Signaling 
 31 
1.6 THIOREDOXIN RELATED PROTEIN OF 14 KDA (TRP14) 
TRP14 was first identified and characterized by the laboratory of Sue Goo Rhee in 2004 257. 
It is a ubiquitous protein with a highly conserved WCPDC active site and most likely a 
predominantly cytosolic protein due to the lack of a signal peptide. As judged by immunoblot 
analysis on rat tissues, it seems to be most abundant in liver, kidney, pancreas and uterus 257. 
In humans, high levels have been indicated in gall- and urinary bladder, parts of the digestive 
system, kidney, ovaries, cerebellum and thyroid gland (according to the human protein atlas, 
www.proteinatlas.org and not verified in follow up studies 372). Recent studies have 
investigated TRP14 in lancelets 373, saltwater clam 374 and a type of cod, showing tissue 
specific expression, as well as antioxidant and metal stress induced functions 375.  
Human TRP14 shares 20% sequence identity with human Trx1 and analyses with different 
cell lines suggest that it is usually present in less amounts than Trx1 163,257. It should be noted 
that TRP14 is a substrate of TrxR1 but not TrxR2, that its pKa and redox potential are lower 
compared to Trx1 and that it does not reduce many typical substrates of Trx1 (RNR, MSR, 
PrxI and insulin) (see Tab. 2). Similar to Trx1, TRP14 possesses three additional Cys. While 
these seem to have regulatory function in Trx1 (see section 1.5.3), they seem to be 
inaccessible in TRP14 257. Suggested substrates for TRP14 are dynein light chain (LC8 or 
DLC8), cofilin, and ribosomal protein L30 376. Whether these proteins are substrates for Trx1 
is currently unknown. TRP14 and Trx1 also have a number of overlapping substrates 
including oxytocin, vasopressin and H2O2. PTP1B is also a common substrate for both 
enzymes, whereas PTEN can only be reduced by Trx1 and not by TRP14 377. The 
phosphatase of regenerating liver (PRL) can neither be reduced by Trx, nor by TRP14 209,378.  
Table 2. Biochemical parameters of Trx1 and TRP14 in comparison. Adapted from 379. 
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The structure of TRP14 shows a similar overall topology compared to Trx1 (Fig.12) 380. 
However, there are several important structural differences that might explain the different 
substrate specificity of both proteins. In TRP14, the helix that corresponds to helix α3 in 
Trx1, is divided into two separate helices (α3a and α3b) with four residues in between. Helix 
α3 is clearly shifted towards the active site and seems to compromise its accessibility. The 
access is furthermore blocked by a protruding loop structure (loop β2-α2), which is seven 
residues longer compared to the equivalent loop in Trx. Both helices and the loop seem to 
significantly influence the substrate accessibility in TRP14. Another important parameter is 
the different hydrogen bonding network in the active site. The residues between the vicinal 
Cys (Gly-Pro in Trx1 and Pro-Asp in TRP14) clearly influence the pKa of the N-terminal 
Cys. The thiolate of Cys43 in TRP14 is stabilized by the partial positive charge of the helix 
α2 dipole and by additional hydrogen bonding between the amide nitrogen of Asp45 and the 
N-terminal Cys sulfur. This bonding network is not possible in Trx1 because of the proline 
residue. Important to note, the surface surrounding the active site is highly charged in TRP14, 
but mainly hydrophobic in Trx1. Comparing the structures, it appears that TRP14 and Trx1 
have evolved to recognize different substrates. The significantly different architecture and 
accessibility of the active site strongly suggests that TRP14 is designed to have a more 
selected set of substrates 380. Interestingly, yeast Grx8 shares the same active site motif as 
human TRP14 and a recent study concluded that both proteins should have evolved in a way 
to constrain the active site to increase substrate specificity 381.  
 
 
Figure 12. Structural comparison of human Trx1 and TRP14. A) Structure of human Trx1 (1ERU). The locations of the 
active site (C32, C35) and additional Cys residues (C62, C69, C73) are indicated in blue. B) Structure of human TRP14 
(1WOU). The active site (C43, C46) and additional Cys residues (C64, C69, C110) are also indicated in blue. C) Overlay of 
human Trx1 (1ERU, grey) with human TRP14 (1WOU, blue). The approximate location of the active site in both structures is 
indicated.  
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TRP14 has been implicated to be involved in the NFκB (nuclear factor kappa light chain 
enhancer of activated B cells) pathway. NFκB regulates the expression of more than hundred 
genes of the immune and inflammatory response and was the first transcription factor 
suggested to be redox regulated and activated by ROS 382,383. Different pathways activate 
NFκB, but for the scope of this thesis focus will be given on the typical, or canonical pathway 
(Fig. 13). This pathway is triggered by e.g. TNFα, IL-1 and LPS, that activate the IκB-kinase 
complex (IKK complex) through phosphorylation, which in turn phosphorylates IκB. This 
leads to a release of IκB from the NFκB complex (typically the p65+p50 complex). IκBs are 
targeted for degradation, while NFκB is phosphorylated by proteinkinase A and translocates 
to the nucleus. There it binds together with its coactivators CREB binding protein (CBP) and 
p300 to the NFκB responsive element 3. The binding requires the reduction of a specific Cys 
residue in the p50 subunit.  
According to recent studies by Rhee and coworkers, Trx1 and TRP14 regulate the NFκB 
pathway differently. The role of Trx1 in NFκB regulation seems to be confined to the 
nucleus, where it reduces the Cys residue in the p50 subunit that in turn enables DNA binding 
(Fig. 13) 234,384,385. The overexpression of Trx1 results in an inhibition of NFκB activation, 
which is most likely an effect on the reduction of the Prxs that compete for hydroperoxides 
that are essential to maintain the NFκB pathway active 232. TRP14, however, appears to have 
a predominant role in the cytosolic regulation of NFκB and was reported to inhibit the TNFα 
induced NFκB activation via its substrate LC8 376. In that study, RNA interference 
experiments showed that depletion of TRP14 resulted in an increase of TNFα induced 
phosphorylation and degradation of IκBα to a greater extent than Trx depletion 376. In a 
follow up study the authors suggested that LC8 acts as a negative regulator of NFκB 386, 
which is consistent with an earlier study, linking TRP14 to prevention of cytosolic NFκB 
activation. How the initial oxidation of LC8 occurs is not clear yet. A direct oxidation by 
H2O2 seems unlikely, but no intermediate proteins have been described 3.  
Several studies have correlated the NFκB activation with an induction of NOX enzymes and 
thereby a simultaneous production of O2-, H2O2 and lipid hydroperoxides 3,33,387,388, which is 
consistent with the suggested concept of localized redox signaling (section 1.2). The role of 
H2O2 in NFκB signaling has been very controversial in the literature, but present consensus 
seems to be that H2O2 is a fine-tuning regulator of NFκB dependent processes 389,390.  
A first hint on the biological significance of NFκB regulation by TRP14 was reported 
recently 391. In this study, TRP14 depletion enhanced the receptor activator of NFκB ligand 
(RANKL) induced osteoclast differentiation, thereby providing evidence for a regulatory role 
of TRP14 in bone resorption.  
Besides its role in NFκB signaling, TRP14 has been associated with chemo-resistance. Based 
on a quantitative proteomics approach, a recent study identified elevated expression of 
TRP14 in chemo-resistant ovarian cancer cells 392. The authors also correlated TRP14 
expression to Beclin 1, a key regulator for autophagy and concluded that TRP14 promotes 
autophagy and chemo-resistance in ovarian cancer. 
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Figure 13. Simplified overview of the putative role of TRP14 in the canonical NFκB pathway. This model has been 
adapted in parts from 379. In unstimulated cells, LC8 binds to IκB and inhibits its phosphorylation by the IKK complex. A 
stimulation of the NFκB pathway activates the IKK complex and leads to a production of H2O2 by NOXs. This can result in 
oxidation and dissociation of LC8 from IκB. IκB is then be phosphorylated by IKK and degraded by the proteasome. The 
NFκB complex (consisting of p65 and p50) can then translocate to the nucleus and initiate gene transcription. LC8 is a 
substrate for TRP14, which coupled to TrxR1, maintains LC8 in a reduced form and thereby counteracts NFκB stimulation. 
Trx1 reduces a critical Cys residue of the NFκB complex in the nucleus, which is required for DNA binding. NFκB-RE: 
NFκB response element, CBP: CREB binding protein. NEMO: NFκB essential modulator.  
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2 PRESENT INVESTIGATION 
2.1 AIMS OF THIS THESIS 
The overall aim of this thesis was to investigate the oxidoreductase TRP14 in different 
contexts.  
Paper I 
• Investigating the inhibition of TrxR1 by noble metal compounds and their effect on 
cancer cell survival.  
• Analyzing the mechanism of inhibition and the potential of forming SecTRAPs in 
cells. 
 
Paper II 
• Studying the role of the Trx system in reactivation of oxidized protein tyrosine 
phoshatases (PTPs) in the context of platelet derived growth factor (PDGF) signaling.  
 
Paper III 
• Characterizing enzymatic properties of TRP14 in reducing disulfide substrates and 
nitrosylated proteins.  
 
Paper IV 
• Developing a method to detect protein persulfides in a cellular context and studying 
the role of the Trx and GSH systems in the reduction of polysulfides and protein 
persulfides.  
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2.2 METHODOLOGY 
This section provides a short introduction into some of the methods used in paper I-IV. For 
more detailed information see the Materials and Methods part of each study. 
Cell culture (paper I-IV) 
Most cell culture experiments described in paper I-IV are based on commercially available 
cell lines (summarized in Tab. 3). For many experiments A549 cells were used, because of 
their exceptionally high levels of TrxR1 336,393. HEK293 cells are commonly known to be a 
good transfection host (source: ATCC), which is why they were used for transient (paper III) 
and stable (paper IV) knockdown of TRP14, Trx1 and TrxR1. Also mouse embryonic 
fibroblasts (MEFs) were used, which have been generated by the laboratories of Marcus 
Conrad (Txnrd1-/-) 226, Edward Schmidt (Txnrd1-/-) 225 and Benjamin Neel (Ptpn1-/-) 394 from 
the respective mice (paper II and IV).  
Table 3. Commercial cell lines used within this thesis. Reference: American Type Culture Collection (ATCC). 
 
 
Activity Assays for TrxR1, Trx1 and TRP14 (paper I-IV) 
We measured the activity of members of the Trx and GSH system in recombinant enzyme 
preparations, as well as in biological samples. Some of the basic principles of these assays are 
summarized in Fig. 14.  
The activity of recombinant TrxR1 can be measured using Ellman’s reagent (5,5-dithio-bis(2-
nitrobenzoic acid), DTNB) 395. TrxR1 directly reduces DTNB to two TNB- molecules, which 
absorb at 412 nm. This method is used to determine the specific activity of TrxR1, because 
one unit (U) of TrxR1 is defined as the amount of enzyme catalyzing the reduction of 1 mol 
DTNB (formation of 2 mol TNB-) per minute.  
Another available assay is the insulin-coupled Trx assay, which can be used to determine the 
activity of Trx1 and TrxR1 in recombinant enzyme preparations as well as in biological 
samples. The assay is typically performed in an endpoint format and involves saturating 
levels of NADPH and insulin as well as a relative excess of either Trx1 or TrxR1, depending 
on which of the proteins is measured 396. The reaction mixture is incubated at 37°C and 
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stopped with guanidine hydrochloride (GuHCl) and DTNB. The number of TNB- ions 
reflects the number of TrxR1- or Trx1-dependent reduced insulin thiols in the sample. In 
contrast to biological samples, recombinant proteins can also be measured by following the 
consumption of NADPH at 340 nm. An option to increase the sensitivity of measuring 
cellular Trx1 is to use fluorescent-labeled insulin 397.  
 
Figure 14. Principles of the activity assays used in this thesis. All reactions depend on the activity of TrxR1.  
In paper III, we established activity assays for TRP14. They base on the same principle as 
Trx1 activity assays, with the difference that TRP14 does not reduce insulin. In contrast, 
cystine and also the fluorescent-labeled Bodipy-cystine are exceptionally good substrates for 
recombinant TRP14 (paper III). The activity of TRP14 in cell extracts has been assessed in 
paper III using cystine as substrate and measuring NADPH consumption at 340 nm. The use 
of Bodipy-cystine in biological samples is still being optimized. 
Grxs are commonly measured using β-hydroxyethylene disulfide (HED) as substrate. The 
reaction is coupled to GSH and GR, whereof the latter uses NADPH that can be measured at 
340 nm 398.  
Measurement of protein nitrosylation and denitrosylation (paper III) 
Analysis of protein nitrosylation is often difficult due to technical limitations, the complex 
chemistry of the reactants and the relative instability of the -SNO moiety. Therefore the use 
of at least two different methods is generally recommended 399.  
One of the most sensitive methods to measure NO is by chemiluminescence detection. In 
paper III a commercially available NO analyzer, that monitors the chemiluminescence of the 
reaction of NO with ozone (O3), was used (Fig. 15) 400. To measure nitrosoproteins, ascorbic 
acid was used in the reaction vessel to maintain a steady-state level of Cu+ over Cu2+, which 
is known to release NO from RSNO moieties 154,401. The reaction of NO with O3 generates 
nitric dioxide in an excited state (NO2*), which decays back to its ground state, thereby 
releasing light. Denitrosylation reactions were thereby monitored by measuring the remaining 
NO content of each sample after certain time intervals using the NO analyzer.  
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Figure 15. Assessment of TRP14 mediated denitrosylation activities using a NO Analyzer. The denitrosylating activity 
of TRP14 or Trx1 is monitored by adding an aliquot of the reaction mixture to the NO analyzer after certain time intervals. In 
the reaction vessel, NO is released by Cu-mediated reduction into the gas phase. There it reacts with ozone (O3) to form 
nitric dioxide in an excited state (NO2*). The latter emits light when decaying to its ground state, which in turn is recorded by 
a detector and plotted against the time (t) course over which the denitrosylation was followed. The area under each peak is 
proportional to the NO released from each injected sample and can be used to determine the rate of denitrosylation. Adapted 
from 400. 
Nitrosoproteins can also be measured with the 2,3-diaminonapthalene (DAN) assay. Here, 
NO is released from SNO bonds by HgCl2, which subsequently reacts with DAN to form a 
fluorescent product 399,402.  
Gene silencing by RNA interference (Paper III and IV) 
In paper III and IV we used RNA interference (RNAi) to induce gene silencing of Trx1, 
TrxR1 and TRP14 – a technique that was awarded the Noble Prize in 2006 403. RNAi is based 
on a cellular post-transcriptional gene regulatory mechanism that uses endogenously 
produced, ~22 nucleotide containing single stranded RNAs to induce gene silencing via the 
RNA induced silencing complex (RISC) that targets specific mRNAs 404. In contrast to small 
interfering (si) RNAs, which only work under transient transfection conditions, plasmid-
based short hairpin RNAs (shRNAs) allow for a direct synthesis of siRNAs in the cell 405 and 
were thus used in papers III and IV. The short RNA sequence folds into a short hairpin and is 
processed by the RNAi machinery to be used by the RISC complex. In addition, a selection 
marker in the plasmid allows for an enrichment of transfected cells and thereby a persistent 
suppression of gene expression in a cell population. Using that approach, we generated a 
stable knockdown of TrxR1 and TRP14 in HEK293 cells in paper IV.  
 
 
Characterization of Thioredoxin Related Protein of 14 kDa and its Role in Redox Signaling 
 39 
3 SUMMARY AND DISCUSSION 
3.1 PAPER I 
Noble metal targeting of thioredoxin reductase – covalent complexes with thioredoxin 
and thioredoxin-related protein of 14 kDa triggered by cisplatin.  
Stefanie Prast-Nielsen*, Marcus Cebula*, Irina Pader, Elias S J. Arnér. 
Free Radicals in Biology and Medicine 49:1765-1778; 2010 
*Equal contribution. 
 
Background 
In this paper, we investigated the effects of noble metal compounds on the activity of TrxR1. 
The platinum (Pt) containing drug cisplatin and the gold (Au) containing drug auranofin are 
noble metal compounds that are in clinical use today; cisplatin against several types of cancer 
and auranofin against rheumatoid arthritis. Earlier studies suggest that the therapeutic effects 
of these compounds are partly due to inhibition of TrxR1 280,406. Here we used chloride salts 
of palladium (Pd), Pt and Au (Fig. 16) together with auranofin and cisplatin to investigate 
differences in the inherent properties of these metals on the inhibition of TrxR1. 
 
Figure 16. Coordination complexes of the noble metal salts used in paper I. A) K2PtCl4, potassium tetrachloroplatinate 
(II) and K2PdCl4, potassium tetrachloropalladate (II). B) K2PtCl6, potassium hexachloroplatinate (IV) and K2PdCl6, potassium 
hexachloropalladate (VI). C) KAuCl4, potassium gold (III) chloride.  
Main findings 
• TrxR1 inhibition by Pt, Pd and Au depends on several parameters   
Using recombinant protein or cell lysates, we found that Pd and Au salts were more 
efficient inhibitors of TrxR1 than Pt salts. In contrast, cellular TrxR1 activity was 
clearly inhibited by Pt and Au compounds (predominantly cisplatin and auranofin), 
whereas the Pd compounds were less potent (Tab. 4). In addition, the ligand 
substituents of the metal compounds influenced the extent of inhibition. 
• Mechanism and SecTRAP formation 
The inhibition of TrxR1 by the noble metal compounds was irreversible. The 
compounds most likely modified the Sec-residue of the enzyme (based on the 
findings that i) prior reduction of TrxR1 by NADPH was necessary and ii) that the 
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inhibited enzyme had a sustained ability to redox cycle with juglone, which is an 
activity of the enzyme known to be independent of an intact Sec). 
• Cisplatin induced complex formation 
With platinum compounds (cisplatin and to some extent K2PtCl4) intracellular 
covalent complexes between TrxR1 and either Trx1 or TRP14 were formed. This 
complex formation was cell-line, time- and cisplatin-concentration dependent. 
 
Table 4. Inhibition profile of TrxR1 using noble metal compounds. 
 
 
 
 
Discussion 
Targeting the Trx system as anti-cancer strategy is still challenging and the underlying 
mechanisms are far from being fully understood. This paper further supports TrxR1 as a 
potential anti-cancer target and strengthens the concept of SecTRAP formation as part of the 
cytotoxic mechanism of targeting TrxR1. 
Severe side effects of cisplatin and the observed high rates of cancers developing resistance to 
the drug propels the need for further development of transition metal based compounds 407-409. 
Based on our findings, new Pd-based anti-cancer drugs may be designed, but other 
parameters that contribute to the pharmacological profile of noble metal compounds clearly 
need to be considered. The inhibitory profile of Pd on TrxR1 is very encouraging, but our 
results suggest that a more efficient uptake of the Pd compound is required. Pd-based 
complexes are closely related to their Pt analogues due to a similar structure and coordination 
chemistry of the two metals. However, the high hydrolysis rates of Pd complexes compared 
to the Pt variants are still problematic and current research focuses on finding ligands that 
slow down the dissociation rates to make them therapeutically more applicable 410. 
Nonetheless, Pd-based complexes are emerging as anti-tumor agents, and the engineering of 
suitable ligands is an active field of research. In line with our results, a recent study 
demonstrated in vitro inhibition of TrxR1 with Pd and Pt complexes, but could similarly not 
correlate it to the cytotoxicity profile, which again emphasizes the importance of suitable 
ligands 411. It will be very interesting to assess emerging Pd-based anti-cancer complexes for 
their inhibitory profile on TrxR1 in cells 412. Intriguing new approaches also try to improve 
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drug delivery and selectivity by encapsulating metal-based drugs in macrocycles or by 
attaching them to nanoparticles 413.  
In the context of cellular TrxR1 inhibition, it is essential to elucidate the exact mechanism, 
e.g. if the complete TrxR1 activity is lost or if the N-terminal active site is still intact, thereby 
potentially forming a cytotoxic SecTRAP. Our results are compatible with the SecTRAP 
hypothesis, as our data suggest a preferential targeting of the Sec residue in TrxR1. We did 
not prove a direct derivatization of the Sec residue via mass spectrometry (MS), but our 
results indirectly show that a targeting of the Sec is likely to be the case. Our data also agree 
with earlier studies that showed the susceptibility of the reduced Sec residue towards 
electrophilic compounds 278 and a direct binding of a Pt(II) complex to the selenolate of 
TrxR1 414.  
As we have already discussed in section 1.5.3, the SecTRAP formation could account for 
parts of the cytotoxic effect and cellular ROS production seen with several electrophilic 
compounds that target the Sec residue in TrxR1. However, the cellular formation and 
mechanisms of SecTRAPs are not very well understood and it is unclear if all TrxR1 
inhibitors promote that effect. Despite the loss of the C-terminal activity of TrxR1, the 
enzyme can still redox cycle via the N-terminal active site with certain compounds, e.g. 
DNCB 415, curcumin 269 and juglone 267, which in turn can lead to O2- production. Also, a 
direct NADPH oxidase activity of TrxR1 in absence of any other substrate is possible 416. 
Currently, the scenario of cellular superoxide production by derivatized TrxR1 is 
conceivable, but not exclusively proven. Nonetheless, SecTRAPs may explain the attenuation 
of cisplatin toxicity in cells expressing a Sec-to-Cys variant of TrxR1 417 and why high levels 
of TrxR1 in A549 cells are critical to the effectiveness of cisplatin 336. For all compounds, 
however, any cellular effects beside TrxR1 inhibition should not be excluded.  
The concept of targeting TrxR1 as anti-cancer strategy is further strengthened by this study, 
because for most of the compounds the inhibition of TrxR1 correlated well with a reduction 
in cell viability. Based on this, our laboratory recently developed a high-throughput screening 
assay to discover novel small molecule inhibitors for TrxR1 418. Based on that assay, a large 
quantitative screen was performed with >300 000 compounds. The lead compound 
irreversibly inhibits TrxR1 in cellular systems in agreement with the SecTRAP concept, and 
also shows anti-cancer efficacy in different mouse models (Stafford et al., manuscript in 
preparation).  
We here also discovered the intracellular formation of covalently linked TrxR1-Trx1 and 
TrxR1-TRP14 complexes upon treatment with cisplatin and K2PtCl4. How the proteins are 
cross-linked is currently unknown and until today, we were unable to resolve the exact nature 
of the complexes via MS. As argued in this paper, all active sites, with the exception of the C-
terminal active site of TrxR1, could be detected via MS, which made it unlikely that the 
complex formation occurred via the active sites. However, the molecular mechanism of 
cisplatin in the cell involves hydrolysis to a potent electrophile that can react with 
nucleophiles including thiol/selenol-groups on proteins and nitrogen atoms on nucleic acids 
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407,419. It therefore seems likely that the complex formation of TrxR1 with Trx1 and TRP14 
respectively occurs via the same mechanism as in DNA crosslinking and therefore 
presumably via the active sites of the enzymes. This is strengthened by a recent study 
showing a crosslink of TrxR1 and Trx1 via their active sites by nitrogen mustard in A549 
cells 420. However, all mechanisms are purely speculative at the moment and further research 
is needed to understand the exact nature of the complex.  
If and how the complexes contribute to the cytotoxic mechanism of cisplatin is currently 
unknown. But the following differences between the Trx1 versus the TRP14 complex 
formation should be noted: i) only a minor fraction of Trx1 compared to basal levels of the 
enzyme seemed to be trapped in the complex as shown with Western Blot, ii) cisplatin 
treatment gave no reduction in overall Trx1 activity and iii) much higher amounts of TRP14 
seemed to be in the complex compared with basal levels of TRP14. The biological relevance 
of the complex formation is unknown, but it could be possible that disruption of TRP14 
mediated pathways could be part of the cytotoxic mechanism of cisplatin. If and how this 
correlates with the concept of SecTRAP formation and if the complex itself works as a 
SecTRAP should clearly be a focus of further studies. Despite the finding that TrxR1 and 
TRP14 associate and seem to interact closely within the cellular context, not much is known 
about this protein. A further characterization thus formed the basis for the other papers 
presented within this thesis.  
This paper does not exclusively provide any evidence that the complex forms under 
physiological conditions. It should certainly be noted, however, that we have recently 
detected the TrxR1-TRP14 complex in liver and kidney of mice that had been treated with 
cisplatin (unpublished). This implies a potential therapeutic effect of the cisplatin mediated 
complex in vivo and should also be further investigated.  
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3.2 PAPER II 
Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-beta 
receptor tyrosine kinase signaling. 
Markus Dagnell, Jeroen Frijhoff, Irina Pader, Martin Augsten, Benoit Boivin, Jianqiang Xu, Pankaj Mandal, 
Nicholas K. Tonks, Carina Hellberg, Marcus Conrad, Elias S. J. Arnér, Arne Östman.  
Proceedings of the National Academy of Sciences USA; 110:(33), 13398-13403; 2013 
 
Background 
In this paper we investigated the reactivation of two different oxidized PTPs, namely PTP1B 
and SHP2, by the Trx system. The stimulation of the platelet-derived growth factor β receptor 
(PDGFβR) typically mediates cell proliferation and migration and results in an oxidation of 
these two PTPs. How they are reactivated, and thereby terminate growth factor signaling is 
still largely unknown. 
Main findings 
• The Trx system can reduce PTP1B but not SHP2 
Using MEFs that lack TrxR1 (Txnrd1-/-) we found that PTP1B oxidation was 
increased and its activity decreased, whereas SHP2 was unaffected. We did not 
observe any changes in overall ROS levels (as determined by CellROX fluorescence), 
suggesting that the increase in PTP1B oxidation was not due to oxidative stress, but 
rather that TrxR1 is required to reduce PTP1B. Using recombinant PTP1B as well as 
immunoprecipitated PTP1B and SHP2 from H2O2-treated NIH3T3 cells, we could 
confirm that oxidized PTP1B but not SHP2, is indeed efficiently reduced by the Trx 
system. Additionally, using a substrate trapping mutant of Trx1 (C35S) we found that 
the active site Cys32 of Trx1 was forming an intermolecular disulfide intermediate 
with PTP1B.  
• The Trx system regulates PDGFβR signaling via PTP1B  
Compared to wildtype MEFs, Txnrd1-/- MEFs showed enhanced PDGFβR 
phosphorylation at Tyr579/581 upon PDGF stimulation. This phosphorylation site is 
known to be regulated by PTP1B. In contrast, we found no changes in the SHP2-
regulated PDGFβR site pY771, which is consistent with SHP2 not being a substrate 
of the Trx system. Phosphorylation at Tyr579/581 is known to promote a growth-
stimulatory response and Txnrd1-/- MEFs consequently showed an increase in 
proliferation. We furthermore used MEFs deficient in PTP1B (Ptpn1-/-) that are also 
characterized by an enhanced phosphorylation of the PDGFβR upon stimulation to 
validate that TrxR1 affects PDGFβR phosphorylation via PTP1B. As expected, 
treatment with the TrxR1 inhibitor auranofin did not increase the phosphorylation of 
PDGFβR in Ptpn1-/- cells, only in MEFs that had been reconstituted with PTP1B 
(hPtpn1).  
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• The Trx system can reactivate PTP1B also via TRP14 
Using recombinant PTP1B, we found that TRP14 can reduce oxidized PTP1B, but 
not SHP2, in a dose dependent manner. This suggests that also TRP14 can contribute 
to the observed differences in PTP1B oxidation and PDGFβR phosphorylation in 
Txnrd1-/- MEFs.  
Discussion 
Cellular signaling via the PDGF receptor has been extensively studied, but detailed 
knowledge of the redox regulation of this pathway still remains elusive 421. Some potential 
mechanisms of redox regulation within PDGF signaling pathways start to unravel and are, for 
a better understanding, summarized in Figure 17. Several reports have established that 
stimulation of the PDGF receptor results in increased H2O2 levels and a concomitant 
oxidation of PTPs 18,24,422. This is most likely mediated via the activation of NOX enzymes by 
the phosphatidylinositol-3 kinase (PI3K) pathway and the GTPase Rac 351,423-425. The NOX 
enzymes produce O2- extracellularly, which rapidly dismutates to H2O2 and is, in turn, 
imported via aquaporins 57. Receptor stimulation has furthermore been linked to PrxI 
inactivation through phosphorylation via the Src kinase, which presumably leads to a 
spatially restricted increase of H2O2 28. The current idea is that phosphatases such as PTP1B 
and SHP2 are inactivated by this local “hotspot” of H2O2, or possibly also by lipid 
peroxides 355,426 and thereby allow for sustained receptor activation and downstream 
signaling. How oxidized PTPs are reduced and thereby PDGF signaling terminated is not 
fully understood. This study shows that oxidized PTP1B can be reactivated by the Trx system 
and thereby provides evidence of a crosstalk between the Trx system and PDGF signaling, 
which is in line with earlier reports 24,365. Similar to the study by Schwertassek et al., we also 
detected a Trx1-PTP1B conjugate using a Trx1-C35S trapping approach. Furthermore, our 
Txnrd-/- MEFs clearly illustrate that a disruption of the Trx system increases the cellular 
PTP1B oxidation state and thereby PDGF signaling. 
This paper further illustrates that the TrxR1-dependent regulation of PTP1B is possibly not 
only mediated via Trx1, but also via TRP14. Using in vitro PTP activity assays, we found 
TRP14 to be less efficient in reactivating PTP1B compared to Trx1, but this nonetheless is 
the first phosphatase to be reported as a substrate for TRP14. Earlier reports could not 
measure any activity of TRP14 with the phosphatases PTEN 377 and PRL 209,378. Additionally, 
both Trx1 and TRP14 were unable to reactivate SHP2, which is interesting regarding the fact 
that the GSH system is reported to be more efficient in reducing SHP1 and SHP2 compared 
to PTP1B 24,427. This suggests selectivity of the Trx and GSH systems in the reactivation of 
certain PTPs.  
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Figure 17. Simplified model of PDGF signaling and its redox regulation. Activated platelets and many other cell types 
including endothelial, epithelial and inflammatory cells secrete PDGFs, which upon binding to PDGFRs results in a 
stimulation of cell growth and proliferation. PDGFRs activate MAP kinase cascades and further non-receptor tyrosine 
kinases, including JAK kinases (JAK-STAT pathway) and Src-family kinases. The activation of phosphatidylinositol-3 
kinase (PI3K) leads to the production of the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), which can 
activate further pathways, including AKT (also known as protein kinase B, PKB). The PI3K pathway leads to an activation of 
NOX enzymes via the small GTPase Rac, resulting in the production of O2-, which undergoes dismutation to H2O2. 
Activated NOX complexes seem to be confined to subcellular compartments, e.g. lipid rafts, thereby generating H2O2 within 
restricted regions of the cell. The activated receptor also induces phosphorylation of cell membrane associated PrxI via Src-
family kinases, resulting in a localized inactivation of PrxI that otherwise would reduce H2O2. The role of PrxII is still 
unclear, it has not been shown to be phosphorylated or hyperoxidized. The localized H2O2 “hotspot” results in an inactivation 
of the PTPs PTP1B and SHP2. The reactivation of oxidized PTP1B and SHP2 can be mediated via the Trx and GSH systems.  
An interesting question to ask is what determines the specificity of the Trx system for PTP1B 
over SHP2? Several factors should be considered, e.g. the molecular and structural basis for 
interaction, which has not been determined yet. Interesting to note, the type of oxidative 
modification might be crucial, especially since PTP1B has been reported to be oxidized (to 
sulfenic acid as well as to sulfenylamide) but also nitrosylated, glutathionylated and 
sulfhydrated 179,317,428,429. The biological context where these modifications occur and how 
they are reversed is still incompletely understood. An aspect that we have not looked into yet 
is the specific cellular localization of redox signaling events. Especially PTP1B is known for 
being spatially confined within the cell 361, and how this relates to its access by members of 
the Trx system should also be part of future studies.  
Future research into redox regulation of PTPs should certainly also include global analyses of 
the oxidation state of PTPs (the “PTPome”) 430. As we are continuously expanding our 
genetic “toolbox” for mouse models of members of the Trx system, future studies have the 
potential to investigate which subsets of PTPs are regulated by e.g. Trx1 and TRP14.   
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3.3 PAPER III 
Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and  
S-denitrosylase. 
Irina Pader*, Rajib Sengupta*, Marcus Cebula, Jianqiang Xu, Jon O. Lundberg, Arne Holmgren,  
Katarina Johansson, Elias S. J. Arnér.  
Proceedings of the National Academy of Sciences U S A; 111(19):6964-6969; 2014 
*Equal contribution. 
 
Background 
The discovery of the cisplatin induced covalent TrxR1-TRP14 complex in Paper I and the 
lack of information about TRP14 at that time encouraged us to further characterize this 
enzyme. We expressed it as a recombinant protein and analyzed its activities in reducing 
disulfides and nitrosothiols in comparison to Trx1.  
Main findings 
• TRP14 is expressed in different human cell lines 
We have determined the expression levels of TRP14 and Trx1 in five different human 
cell lines, which revealed that different cells express different amounts of the two 
proteins. TRP14 is expressed in all cell types, but generally in lower amounts 
compared to Trx1.  
• TRP14 is an efficient TrxR1-dependent reductase  
We established activity assays for TRP14 and found that both TRP14 and Trx1 can 
reduce cystine, HED and H2O2. Importantly, TRP14 seems to be a qualitatively more 
dedicated cystine reductase in cells because i) it is approx. fivefold more efficient than 
Trx1 and ii) in contrast to Trx1, its activity with cystine was not affected by the 
presence of another protein disulfide substrate of Trx1, such as insulin. In contrast to 
Trx1, TRP14 is not inhibited with higher concentrations of H2O2. Furthermore, both 
TRP14 and Trx1 required TrxR1 as an electron donor and could not be reduced by 
GSH coupled to GR.  
• TRP14 is a TrxR1-dependent denitrosylase 
We found that both TRP14 and Trx1 can reduce nitrosothiols including GSNO, 
nitroso-caspase 3 (caspase 3-SNO) and nitroso-cathepsin B (cathepsin-SNO). In 
addition, both proteins could reduce a mixture of nitrosylated proteins from HEK293 
cell lysates. 
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Discussion 
It was previously thought that Trx1 alone is the most significant substrate of TrxR1. 
However, we have found that TrxR1 can reduce TRP14 as efficiently as Trx1, making it an 
integral component of the Trx system. 
Our data showing that TRP14 is expressed in a variety of cell lines, agrees well with the first 
study by Jeong et al. identifying TRP14 as a ubiquitous cellular oxidoreductase with a tissue 
specific expression pattern 257. The subcellular localization of TRP14 has not been 
exclusively determined yet. It seems to be a predominantly cytosolic protein (which agrees 
with our hypothesis that it is acting in the cytosol in parallel with Trx1), but it also might 
exert its function in other cellular compartments. An interesting possibility is for example 
nuclear translocation to regulate transcription factor binding as shown for Trx1. 
Earlier reports have suggested a crosstalk between the Trx and the GSH systems, e.g. that 
TrxR1 can reduce Grx2 259 and that Grx1 coupled to GR and GSH acts as a backup reducing 
system for Trx1 241,431. Based on this we tested if GSH may be able to donate electrons to 
TRP14 or Trx1, but found this not to be the case. However, if Grxs can instead catalyze the 
electron transfer to TRP14 is currently unknown and should be followed up in future studies.  
To this day the exact mechanisms of the intracellular reduction of cystine are still debated. 
Earlier studies have suggested that once cystine is imported via system XC-, it is rapidly 
reduced by either the GSH or the Trx system 124,125. Our hypothesis is that due to the 
exceptional high in vitro activity, TRP14 instead of Trx1 likely contributes to the cytosolic 
cystine reduction. This was further strengthened by our observation that Trx1 does not reduce 
cystine once a preferred substrate like insulin is present. We concluded that Trx1 has a variety 
of intracellular substrates; whereas TRP14 is much more specific and can reduce cystine 
while Trx1 is “occupied” with its basal cellular functions (e.g. RNR). One should, however, 
not rule out the possibility that cystine reduction could also be mediated via GSH-dependent 
enzymes and further studies are needed to establish the primary cystine reduction mechanism 
in cells. Another aspect of cystine reduction that we have not looked into yet is the rather new 
field of cysteinylation as a posttranslational modification. A few studies have demonstrated 
cysteinylation as a protective mechanism to shield thiols from irreversible oxidation 432-435 
and it will be very interesting to investigate if TRP14 could function as a regulator of protein 
cysteinylation.  
Interestingly, the reduction of H2O2 by TRP14 is, in contrast to Trx1, maintained at high 
concentrations. As we have already discussed in the paper, the used concentrations of H2O2 
most likely do not represent physiological concentrations, but suggest that TRP14 could still 
be functional under conditions of oxidative stress. Also the results we obtained with SDS-
PAGE, should evidently be followed up in further studies. As determined earlier with 
DTNB 257 and judged from the structure (section 1.6), the additional Cys of TRP14 do not 
seem to be surface exposed. However, TRP14 clearly forms oligomers via amino acid 
residues outside the active site, which suggests different structural dynamics and regulation 
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compared to Trx1. We were not able to express a TRP14 variant where the additional Cys 
residues were mutated to alanines (unpublished), which suggested that they are at least 
partially required for the structural integrity of the protein. Future experiments are clearly 
needed to assess the accessibility of the additional Cys residues and to elucidate if potentially 
other surface exposed residues could be involved in the regulation of TRP14.  
In this paper we furthermore provide evidence that TRP14 is another TrxR1-dependent 
denitrosylase. Other members of the Trx family, including Trx1 and PDI, have earlier been 
reported to act as denitrosylases 153,155,156. The study by Benhar et al., assessed TRP14-
depleted lysates of HeLa cells for denitrosylating activity on caspase 3-SNO, which 
compared to Trx1-depletion, was unaffected 153. Considering our results from protease 
activity assays and the NO analyzer we still hypothesize that TrxR1 can mediate denitosylase 
activity via both Trx1 and TRP14. In addition, the knockdown and overexpression of TRP14 
in our experiments clearly had an effect on the levels of cellular nitrosoproteins in HEK293 
cells. We therefore suggest that the contributions of Trx1- vs. TRP14- mediated 
denitrosylation in vivo certainly depends on the cell type and the specific nitrosylated protein 
substrate, which should evidently be the focus of further studies. Specific nitrosylated protein 
substrates of TRP14 are currently unknown, but we have started a mass spectrometry based 
substrate trapping approach using a TRP14 active site “trapping mutant” as previously 
described for Trx1 169. This approach will certainly contribute to a better understanding of the 
role of TRP14-mediated denitrosylation in a cellular context.  
This study should emphasize that TRP14 is another, yet sparsely characterized, member of 
the Trx system with redox activities that are complementing those of Trx1.  
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3.4 PAPER IV 
Novel persulfide detection method reveals protein persulfide and polysulfide reducing 
functions of thioredoxin- and glutathione systems. 
Éva Dóka, Irina Pader, Adrienn Bíró, Katarina Johansson, Qing Cheng, Krisztina Ballagó, Justin R. Prigge, 
Daniel Pastor-Flores, Tobias P. Dick, Edward E. Schmidt, Elias S. J. Arnér, Péter Nagy. 
Science Advances 2:e1500968, 2016 
Background 
To overcome challenges and uncertainties of previous detection methods, we here developed 
and validated a novel method to detect persulfides of recombinant proteins and in biological 
samples (Protein Persulfide Detection Protocol, ProPerDP). In addition, reduction pathways 
for poly- and persulfides are still largely unknown. We therefore used the ProPerDP method 
to investigate the role of the Trx and GSH systems on these sulfur modifications. 
Main findings 
• Development and validation of ProPerDP  
ProPerDP is based on three steps: i) the alkylation of thiol and persulfide groups with 
Iodoacetyl-PEG2-Biotin, ii) subsequent pull down by Streptavidin and iii) reduction 
with DTT. The last step will only cleave, and thereby detach from the Streptavidin, 
the alkylation products originating from protein persulfides in the sample (R-SS-
alkylating agent) and not from thiols (R-S-alkylation agent) (for a detailed scheme of 
the method see Fig. 1 in paper IV). Using human albumin as a model system to 
validate this method we could detect persulfidation on recombinant protein as well as 
in polysulfide treated human plasma. We furthermore detected protein persulfides in 
HSx- treated A549 cells and identified several proteins known toe be susceptible to 
persulfidation using mass spectrometry. In addition, CBS and CSE deleted yeast 
strains showed lower levels of protein persulfides, thereby further validating 
ProPerDP.  
• Roles of the Trx and GSH systems in the reduction of poly- and persulfides 
We first tested the reduction of polysulfides and albumin persulfide in vitro. Both 
could directly be reduced by TrxR1 and required an intact Sec residue in the active 
site. The activity was further enhanced by adding Trx1 or TRP14 to the reaction 
mixture. Additionally, polysulfides and albumin persulfide could be reduced by GSH 
coupled to GR, which was further enhanced by adding Grx1. While assessing the 
reduction of persulfides in a cellular context we found elevated levels of protein 
persulfides upon stable knockdown of TrxR1 and TRP14 in HEK293 cells. To further 
establish in vivo relevance and suitability of the assay for tissue samples, we assessed 
protein persulfides in mouse liver and found higher levels of protein persulfides in 
livers that lack GR (“GR null”) as well as both TrxR1 and GR (“TR/GR null”). 
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Discussion 
Until today, the development of detection methods for persulfides remains challenging due to 
the similarity of the persulfide (-S-SH) and thiol (-SH) moiety. We therefore developed a 
method that is more sensitive and can moreover be used to study persulfidation in intact cells, 
which is not possible with previously described methods (Fig. 18): 
• Modified Biotin Switch Assay (Fig. 18A)  
The Modified Biotin Switch Assay was the first method available to detect protein 
persulfides and is used in its original form to detect protein S-nitrosylation 141,436. The 
essential steps in the original Biotin Switch Assay are i) blocking of thiols with 
methylmethanthiosulfonate (MMTS), ii) conversion of nitrosothiols to thiols via 
transnitrosylation with ascorbate and iii) S-biotinylation of the previously nitrosylated 
thiols with Biotin-HPDP. In contrast, the Modified Biotin Switch Assay only requires 
steps i) and iii) 91. Persulfides are believed to not react with MMTS, thus they are 
available for conjugation with biotin-HPDP in step iii). However, the essential 
assumption that MMTS does not react with persulfides has been questioned due to the 
higher nucleophilicity of -SSH moieties compared to -SH moieties 437.  
• Cysteinyl-labeling assay (Fig. 18B)  
Another recently developed method bases on the previously established PTP cysteinyl-
labeling assay 179,438. Here, in step i) both -SSH and -SH moieties are blocked using 
alkylating agents such as iodoacetic acid (IAA) or iodoacetamide (IAM). Subsequently, 
in step ii) the persulfide adducts are reduced by DTT to form free SH groups, which in 
step iii) are labeled with IAM-linked Biotin. The disadvantage with this protocol is that 
the DTT reducing step is not selective for the persulfide adducts. Protein disulfides will 
also be reduced by DTT and labeled in step iii).  
• Tag-Switch Assay (Fig. 18C) 
In the first step i), -SH and -SSH moieties are labeled with methylsulfonyl benzothiazole 
(MSBT). Subsequenltly ii) biotinylated cyanoacetate (CN-Biotin) is added and thought to 
only react with -SS-MSBT thereby “switching” the persulfide tag to -SS-CN-Biotin 175. 
However, a background reaction with protein disulfides is possible and has not been 
experimentally excluded yet.  
• Maleimide Assay (Fig. 18D) 
The maleimide assay is based on the modification of free thiols and persulfides with a 
fluorescently labeled maleimide compound 178. A subsequent treatment with DTT cleaves 
disulfide bonds and thereby detaches the fluorescent label from persulfides, but not 
unpersulfidated proteins, which can be visualized by in-gel fluorescence. The advantage 
is that it is relatively specific, but does not allow for a direct persulfide labeling for e.g. 
proteomic analysis. 
ProPerDP (Fig. 18E) has the advantage that it can be used on intact cells to study sulfide 
signaling in a more physiological relevant setting. Our validation experiments have 
furthermore demonstrated its specificity and reliability. However, a drawback with this 
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method is that proteins with extra thiol groups that are IAB labeled may not be detected. 
While other methods can easily give false-positive information, ProPerDP thus runs the risk 
of losing persulfidated proteins in the DTT reduction step. The suggested mass-spectrometry 
based method improvement is currently under development.  
 
Figure 18. Principles of the currently available methods to detect protein persulfides. For details, see main text.  
Using this method, several questions can be addressed in the future. Which proteins are 
regulated in vivo via persulfide modifications? Which of them are reduced by the GSH and 
the Trx system, respectively? And within the Trx system, what are the relative contributions 
of Trx1 versus TRP14? Both NADPH-dependent reductase systems are able to reduce poly- 
and persulfides in vitro, which is further supported by our experiments with the stable 
knockdown HEK293 cells and the TR/GR null mouse livers. However, a direct comparison 
of the relative efficiencies of both systems in vitro is difficult and future genetic models are 
needed to elucidate specific physiological persulfide signaling mechanisms. In analogy to S-
nitrosylation, a persulfide based trapping approach using Trx1 and TRP14 proteins as “baits” 
is conceivable and could shed light on the regulation of specific signaling pathways.  
Future challenges also include the crosstalk of sulfide and NO signaling. This relatively new 
area of research is not without controversies, but in consideration of the reducing activities of 
Trx1 and TRP14 for both nitrosothiols and protein persulfides, future experiments are clearly 
required to understand mechanistic principles and the underlying physiological relevance.
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
Within this thesis we have investigated the redox protein TRP14 in different contexts. We 
have focused on a biochemical characterization and obtained indications for its functions in 
cancer chemotherapy, growth factor signaling as well as nitric oxide and sulfide signaling 
respectively. All herein presented results cumulatively suggest that TRP14 is a substantial, 
and likely underestimated, member of the Trx system. It is important to emphasize that 
TRP14 is a substrate for TrxR1, which until its initial characterization in 2004 was unknown. 
Our results here clearly show that TrxR1 powered reactions do not necessarily have to be 
mediated through Trx1, but depending on the final substrate can also occur via TRP14. In 
theory, it is possible that many functions that had so far been attributed only to Trx1, could 
also be mediated via TRP14.  
A major challenge for future experiments will be to identify specific substrates for TRP14 
and to elucidate its role in relation to other members of the Trx system. During the progress 
of this thesis we have not followed up on earlier published substrates, e.g. cofilin, LC8 and 
L30 257. Among them, cofilin seems to be a promising candidate to investigate with regards to 
TRP14. Cofilin is an essential component of actin dynamics in cell migration and its 
oxidation has been related to the activity of NOXs and the induction of apoptosis 439-441. 
Further work will certainly shed more light on the potential redox regulation of the cell 
cytoskeleton by TRP14.  
Redox processes can regulate cell survival at several different levels, including signal 
transduction cascades, transcription factors and cell death pathways 442. How is TRP14 
involved in these redox-signaling processes? At this stage we can only speculate because i) 
we lack definite in vivo evidence and ii) we have not identified any specific substrates for 
TRP14 (compared to Trx1) yet. It seems that TRP14 has structurally evolved to reduce a 
more restricted set of substrates compared to Trx1, but as of today, there are also many 
overlapping functions and further experiments are needed. Nevertheless, the results presented 
here indicate that TRP14 could be involved in all levels of redox regulation for cell survival. 
Growth factor induced signaling cascades, e.g. by EGF, PDGF and insulin, involve an 
inactivation of PTP1B, which we have here found to be reactivated by TRP14 (paper II). 
Earlier reports have established a modulatory role of TRP14 on the redox regulated 
transcription factor NFκB 379. In addition, our results in paper III point towards a regulatory 
role in apoptosis signaling involving caspases and cathepsins. Already ongoing experiments 
will help for a more comprehensive understanding of the cellular functions of TRP14: 
• In collaboration with Moran Benhar in Israel we have initiated the already mentioned 
“trapping” approach to screen for specific nitrosylated protein substrates of TRP14, 
which his laboratory has successfully applied with Trx1 169.  
• In collaboration with Ed Schmidt in the USA, we are currently developing novel 
mouse models for whole-animal and conditional tissue-specific deletion of Txndc17, 
the gene encoding TRP14. His laboratory has already developed several genetically 
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engineered mouse models with distinct aberrations of key redox enzymes (TrxR1, 
Trx1 and GR). Given that TRP14 has earlier been suggested to be involved in 
inflammatory signaling cascades and bone remodeling, the new mouse models will 
certainly provide some more insights into the physiological functions of TRP14.  
• Besides NFκB, a variety of transcription factors have been recognized to be redox-
regulated 3. How the Trx system can modulate these transcription factors is largely 
unknown. We have recently developed a new tool, pTRAF (plasmid for transcription 
factor reporter activation based upon fluorescence), which can be used to determine 
the activities of three different transcription factors simultaneously within single 
cells 443. We are currently using the pTRAF technology together with the stable 
TRP14 and TrxR1 knockdown HEK293 cells (paper IV) in order to investigate if and 
how the Trx system and especially TRP14, is involved in the regulation of any of the 
transcription factors NFκB, Nrf2 and HIF-1.  
To summarize, the aim of this PhD project was to examine and characterize TRP14 in 
different aspects. Within this thesis we thus expanded the knowledge of TRP14 by providing 
evidence of its potential functions in redox regulated signaling pathways (Fig. 19).  
 
Figure 19. Schematic overview of the findings of paper I-IV in relation to TRP14. For simplicity, the functions of the Trx 
and the GSH system are omitted. Paper 1: Cisplatin induced complex between TrxR1 and TRP14 and potential SecTRAP 
formation. Paper 2: Reduction and thereby activation of oxidized PTP1B by TRP14. Paper 3: Reduction of cystine and 
nitrosothiols by TRP14. Paper IV: TRP14 mediated reduction of polysulfides (HSx-) and protein persulfides.  
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